PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3988955-3	1985	The paper establishes the diagnosis as alpha 2-antiplasmin deficiency and describes its management with oral tranexamic acid.	Tranexamic Acid	109-124	serpin family F member 2	Homo sapiens	39-58
6201189-2	1984	Clearance of the complexes from the blood is rapid and their detection thus implies active plasmin generation at the time of blood sampling or within the preceding 24 h. Abolition of the complexes using tranexamic acid therapy allowed surgery without bleeding in two previously grossly haemorrhagic patients in group (c).	Tranexamic Acid	203-218	plasminogen	Homo sapiens	91-98
6367528-0	1984	Inhibition of the late phase reaction to anti-human IgE in man by oral tranexamic acid.	Tranexamic Acid	71-86	immunoglobulin heavy constant epsilon	Homo sapiens	52-55
6806950-5	1982	To prevent degradation of VIII:C by fibrinolysis, tranexamic acid was added to the plasma from treated donors immediately after separation from the red blood cells.	Tranexamic Acid	50-65	cytochrome c oxidase subunit 8A	Homo sapiens	26-30
6347401-8	1983	The plasmin esterase inhibitors, epsilon-amino-n-caproic acid, tranexamic acid, and L-lysine, previously established to reverse the MMI response to MIF, FBP, and C3 activators were found to inhibit both Fc- and C3-dependent phagocytosis.	Tranexamic Acid	63-78	macrophage migration inhibitory factor	Ovis aries	148-151
6347401-8	1983	The plasmin esterase inhibitors, epsilon-amino-n-caproic acid, tranexamic acid, and L-lysine, previously established to reverse the MMI response to MIF, FBP, and C3 activators were found to inhibit both Fc- and C3-dependent phagocytosis.	Tranexamic Acid	63-78	fructose-1,6-bisphosphatase 1	Ovis aries	153-156
6347401-8	1983	The plasmin esterase inhibitors, epsilon-amino-n-caproic acid, tranexamic acid, and L-lysine, previously established to reverse the MMI response to MIF, FBP, and C3 activators were found to inhibit both Fc- and C3-dependent phagocytosis.	Tranexamic Acid	63-78	complement C3	Ovis aries	203-213
6449829-0	1980	Activation of factor XII in plasma from rats pretreated with tranexamic acid.	Tranexamic Acid	61-76	coagulation factor XII	Rattus norvegicus	14-24
7047313-10	1982	In rats treated with AMCA + thrombin a similar decrease in fibrinogen levels was recorded, the EGT was positive in all animals, and extensive fibrin deposits were observed in the kidneys and lungs of the animals.	Tranexamic Acid	21-25	coagulation factor II	Rattus norvegicus	28-36
6459779-3	1981	This binding is decreased by alpha(2)-plasmin inhibitor and tranexamic acid, and is, in the latter case, related to saturation of a strong lysine-binding site.	Tranexamic Acid	60-75	plasminogen	Homo sapiens	38-45
7095605-7	1982	Bleeding episodes due to deficiency of alpha 2-PI in these patients were well controlled by an antifibrinolytic agent, tranexamic acid.	Tranexamic Acid	119-134	serpin family F member 2	Homo sapiens	39-49
6449829-2	1980	Incubation of plasma from rats pretreated with tranexamic acid (40 mg/100 g) with acetone (23% V/V) yielded enzyme preparations in which all the plasminogen present was recovered as plasmin and a plasmin-like substance without affinity for lysine-Sepharose.	Tranexamic Acid	47-62	plasminogen	Homo sapiens	145-152
6449829-2	1980	Incubation of plasma from rats pretreated with tranexamic acid (40 mg/100 g) with acetone (23% V/V) yielded enzyme preparations in which all the plasminogen present was recovered as plasmin and a plasmin-like substance without affinity for lysine-Sepharose.	Tranexamic Acid	47-62	plasminogen	Homo sapiens	182-189
725719-5	1978	The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects.	Tranexamic Acid	84-88	serine peptidase inhibitor Kazal type 6	Homo sapiens	113-133
6450467-10	1980	Plasmin stability is improved in the presence of AMCHA.	Tranexamic Acid	49-54	plasminogen	Homo sapiens	0-7
6447383-7	1980	In an even purified system, clot formation and the presence of tranexamic acid protected plasmin from its inactivation by alpha 2PI to some extent.	Tranexamic Acid	63-78	plasminogen	Homo sapiens	89-96
6447383-7	1980	In an even purified system, clot formation and the presence of tranexamic acid protected plasmin from its inactivation by alpha 2PI to some extent.	Tranexamic Acid	63-78	serpin family F member 2	Homo sapiens	122-131
117680-3	1979	Evidence that tranexamic acid, a potent antiplasmin compound, provided an inhibitory effect on the cold activation of complement, suggested that the phenomenon could not be explained by a single mechanism, and plasmin might be involved in the phenomenon in a limited case.	Tranexamic Acid	14-29	plasminogen	Homo sapiens	44-51
150862-1	1978	The effects of L-lysine, 6-aminohexanoic acid, and trans-4-aminomethylcy-clohexane-1-carboxylic acid on the catalytic activity of plasmin (EC 3.4.21.7) have been investigated.	Tranexamic Acid	51-100	plasminogen	Homo sapiens	130-137
6157220-0	1980	Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.	Tranexamic Acid	105-120	plasminogen	Homo sapiens	15-22
6447383-0	1980	Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot.	Tranexamic Acid	28-43	plasminogen	Homo sapiens	15-22
6447383-1	1980	Interaction of urokinase (UK) activated plasmin with tranexamic acid and alpha 2 plasmin inhibitor (alpha 2PI) was studied by using a chromogenic substrate (S-2251) and immunoelectrophoresis.	Tranexamic Acid	53-68	plasminogen	Homo sapiens	40-47
1188708-4	1975	In normal rat, heparin (2.5 mg/kg), acetylsalicylic acid (30 mg/kg) and tranexamic acid (100 mg/kg) suppressed specifically coagulation, platelet aggregation induced by collagen or thrombin and fibrinolysis respectively.	Tranexamic Acid	72-87	coagulation factor II	Rattus norvegicus	181-189
1203093-2	1975	A decreased level of the C1 esterase plasma inhibitor was found in both the patients, who were treated with tranexamic acid with a slight, but definite improvement.	Tranexamic Acid	108-123	complement C1s	Homo sapiens	25-36
125463-1	1975	Specific binding of tranexamic acid to plasmin.	Tranexamic Acid	20-35	plasminogen	Homo sapiens	39-46
125463-4	1975	On the other hand, tranexamic acid bound to human plasmin with a dissociation constant of 3.5 X 10-5 M, which was very close to the inhibition constatn (3.6 X 10-5 M1 for this compound in inhibiting plasmin-induced fibrinolysis.	Tranexamic Acid	19-34	plasminogen	Homo sapiens	50-57
125463-4	1975	On the other hand, tranexamic acid bound to human plasmin with a dissociation constant of 3.5 X 10-5 M, which was very close to the inhibition constatn (3.6 X 10-5 M1 for this compound in inhibiting plasmin-induced fibrinolysis.	Tranexamic Acid	19-34	plasminogen	Homo sapiens	199-206
125463-5	1975	The binding site of tranexamic acid on plasmin was not the catalytic site of plasmin, because TLCK-blocked plasmin also showed a similar affinity to tranexamic acid (the dissociation constant, 2.9-4.8 x 10-5m).	Tranexamic Acid	20-35	plasminogen	Homo sapiens	39-46
125463-5	1975	The binding site of tranexamic acid on plasmin was not the catalytic site of plasmin, because TLCK-blocked plasmin also showed a similar affinity to tranexamic acid (the dissociation constant, 2.9-4.8 x 10-5m).	Tranexamic Acid	149-164	plasminogen	Homo sapiens	39-46
561325-8	1977	Fibrinogen showed a tendency to increase gradually after the administration of t-AMCHA, and this increase of fibrinogen would be one of the alarming signs of the development of ischemic complications.	Tranexamic Acid	79-86	fibrinogen beta chain	Homo sapiens	0-10
561325-8	1977	Fibrinogen showed a tendency to increase gradually after the administration of t-AMCHA, and this increase of fibrinogen would be one of the alarming signs of the development of ischemic complications.	Tranexamic Acid	79-86	fibrinogen beta chain	Homo sapiens	109-119
125463-6	1975	in the binding studies with the highly purified plasminogen and TLCK-plasmin preparations which were obtained by affinity chromatography on lysine-substituted Sepharose, the molar binding ratio was shown to be 1.5-1.6 moles tranexamic acid per one mole protein.	Tranexamic Acid	224-239	plasminogen	Homo sapiens	48-55
5022796-0	1972	Effect of 4-aminomethylcyclohexanecarboxylic acid on fibrinogen turnover.	Tranexamic Acid	10-49	fibrinogen beta chain	Homo sapiens	53-63
4251764-2	1970	Potentiation of antifibrinolytic action of a synthetic inhibitor, tranexamic acid, by alpha 2-macroglobulin antiplasmin.	Tranexamic Acid	66-81	alpha-2-macroglobulin	Homo sapiens	86-107
33164754-0	2021	Tranexamic acid for ACE inhibitor induced angioedema - A case report.	Tranexamic Acid	0-15	angiotensin I converting enzyme	Homo sapiens	20-23
5235628-0	1967	[Effects of tranexamic acid on bradykinin action].	Tranexamic Acid	12-27	kininogen 1	Homo sapiens	31-41
5298721-0	1966	Tranexamic acid enhances bradykinin--induced venoconstriction.	Tranexamic Acid	0-15	kininogen 1	Homo sapiens	25-35
33975621-0	2021	Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	101-104
33164754-2	2021	Tranexamic acid is used in prophylactic management of hereditary angioedema; however, evidence for TXA in angiotensin converting enzyme (ACE) inhibitor-induced angioedema (ACEI-AE) is limited.	Tranexamic Acid	99-102	angiotensin I converting enzyme	Homo sapiens	137-140
33164754-1	2021	Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	80-87
33164754-1	2021	Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation.	Tranexamic Acid	0-15	kininogen 1	Homo sapiens	144-154
33164754-1	2021	Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	80-87
33164754-1	2021	Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation.	Tranexamic Acid	17-20	kininogen 1	Homo sapiens	144-154
33470644-0	2021	Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator-induced hyperfibrinolysis in full-term pregnant women: a prospective interventional study.	Tranexamic Acid	10-25	plasminogen activator, tissue type	Homo sapiens	62-95
33713439-0	2021	Tranexamic acid in patients with current or former cancer undergoing hip and knee arthroplasty.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	69-72
33834598-3	2021	OBJECTIVE: To determine if bovine and equine AMH reduce in vitro MMP-2 and MMP-9 activities associated with the presence of TIMPs.	Tranexamic Acid	45-48	matrix metallopeptidase 2	Equus caballus	65-70
33834598-3	2021	OBJECTIVE: To determine if bovine and equine AMH reduce in vitro MMP-2 and MMP-9 activities associated with the presence of TIMPs.	Tranexamic Acid	45-48	matrix metallopeptidase 9	Equus caballus	75-80
33834598-7	2021	RESULTS: AMH from both species were able to inhibit MMP-2 and MMP-9 activities in vitro, and the inhibition efficacy decreased gradually with dilution.	Tranexamic Acid	9-12	matrix metallopeptidase 2	Bos taurus	52-57
33834598-7	2021	RESULTS: AMH from both species were able to inhibit MMP-2 and MMP-9 activities in vitro, and the inhibition efficacy decreased gradually with dilution.	Tranexamic Acid	9-12	matrix metallopeptidase 9	Bos taurus	62-67
33857300-0	2021	Safety of Tranexamic Acid in Hip and Knee Arthroplasty in High-risk Patients.	Tranexamic Acid	10-25	hedgehog interacting protein	Homo sapiens	29-32
33857300-1	2021	BACKGROUND: With increasing use of tranexamic acid in total hip and knee arthroplasties, safety concerns remain.	Tranexamic Acid	35-50	hedgehog interacting protein	Homo sapiens	60-63
33443933-0	2021	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	72-79
33443933-1	2021	Tranexamic acid (TXA) is a lysine analogue that inhibits plasmin generation and has been used for decades as an antifibrinolytic agent to reduce bleeding.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	57-64
33470644-4	2021	The objective of our prospective observational ex-vivo study was to define the effective TXA concentration required to inhibit 95% (EC95) of tissue-type plasminogen activator (t-PA)-induced fibrinolysis in full-term pregnant women.	Tranexamic Acid	89-92	plasminogen activator, tissue type	Homo sapiens	141-174
33443933-1	2021	Tranexamic acid (TXA) is a lysine analogue that inhibits plasmin generation and has been used for decades as an antifibrinolytic agent to reduce bleeding.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	57-64
33470644-4	2021	The objective of our prospective observational ex-vivo study was to define the effective TXA concentration required to inhibit 95% (EC95) of tissue-type plasminogen activator (t-PA)-induced fibrinolysis in full-term pregnant women.	Tranexamic Acid	89-92	plasminogen activator, tissue type	Homo sapiens	176-180
33443933-2	2021	Recent reports have indicated that TXA can paradoxically promote plasmin generation.	Tranexamic Acid	35-38	plasminogen	Homo sapiens	65-72
33665997-15	2021	CONCLUSION: Preoperative application of tranexamic acid could effectively reduce blood loss in arthroscopy for femoroacetabular impingement, thereby improving surgical field of vision, reducing difficulty of surgical operation, which could promote early and rapid rehabilitation of hip function.	Tranexamic Acid	40-55	hedgehog interacting protein	Homo sapiens	282-285
33443933-8	2021	t-PA and u-PA-induced clot lysis were both inhibited in plasma from TXA-treated patients.	Tranexamic Acid	68-71	plasminogen activator, tissue type	Homo sapiens	0-4
33443933-8	2021	t-PA and u-PA-induced clot lysis were both inhibited in plasma from TXA-treated patients.	Tranexamic Acid	68-71	plasminogen activator, urokinase	Homo sapiens	9-13
33443933-9	2021	In contrast, PAP complex formation, representing plasmin generation, was unexpectedly enhanced in the plasma of patients administered TXA at the EOS time point.	Tranexamic Acid	134-137	plasminogen	Homo sapiens	49-56
33443933-11	2021	Our findings demonstrate that TXA can actually augment PAP complex formation, consistent with an increase in plasmin generation in vivo despite the fact that it blocks fibrinolysis within 30 min.	Tranexamic Acid	30-33	plasminogen	Homo sapiens	109-116
33127237-0	2021	Tranexamic Acid Administration is Associated With a Decreased Odds of Prosthetic Joint Infection Following Primary Total Hip and Primary Total Knee Arthroplasty: A National Database Analysis.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	121-124
33346399-7	2021	In addition, tranexamic acid alone is effective for Low VWF patients undergoing non-dental minor procedures.	Tranexamic Acid	13-28	von Willebrand factor	Homo sapiens	56-59
33648325-8	2021	CONCLUSION: TXA has been widely implemented in EMS protocols since the CRASH (Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage) trials.	Tranexamic Acid	12-15	asparaginase and isoaspartyl peptidase 1	Homo sapiens	71-76
33915859-11	2021	TXA administration was associated with reduced syndecan-1 shedding in patients undergoing posterior lumbar fusion surgery.	Tranexamic Acid	0-3	syndecan 1	Homo sapiens	47-57
33788803-0	2021	The Use of Tranexamic Acid in Hip and Pelvic Fracture Surgeries.	Tranexamic Acid	11-26	hedgehog interacting protein	Homo sapiens	30-33
33553549-1	2021	Background: The optimal route and dosing regimen of tranexamic acid (TXA) in primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain unclear.	Tranexamic Acid	52-67	hedgehog interacting protein	Homo sapiens	91-94
33553549-1	2021	Background: The optimal route and dosing regimen of tranexamic acid (TXA) in primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain unclear.	Tranexamic Acid	69-72	hedgehog interacting protein	Homo sapiens	91-94
32809062-10	2021	Postpartum tranexamic acid oral dosage should be discussed when fibrinogen levels are decreasing and D-Dimers are increasing.	Tranexamic Acid	11-26	fibrinogen beta chain	Homo sapiens	64-74
33496410-0	2021	Tranexamic acid for head injuries: on the CRASH-3 trial.	Tranexamic Acid	0-15	asparaginase and isoaspartyl peptidase 1	Homo sapiens	42-47
33529783-1	2021	PURPOSE: The purpose of this double-blinded randomized controlled trial was to evaluate the use of intravenous (IV) tranexamic acid (TXA) in patients undergoing primary bone-patella tendon-bone (BTB) ACLR with regard to post-operative hemarthrosis, pain, opioid consumption, quadriceps atrophy and activation.	Tranexamic Acid	116-131	solute carrier family 35 member G1	Homo sapiens	220-224
33001565-0	2021	Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery.	Tranexamic Acid	79-94	plasminogen	Homo sapiens	17-24
33518674-0	2021	Tranexamic Acid Improves the Disrupted Formation of Collagen and Fibrillin-1 Fibers Produced by Fibroblasts Repetitively Irradiated with UVA.	Tranexamic Acid	0-15	fibrillin 1	Homo sapiens	65-76
33518674-5	2021	Tranexamic acid (TXA), which is an anti-inflammatory medicine that inhibits plasmin, reduces the level of PGE2 secreted following UV exposure or after inflammatory stimulation.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	76-83
33518674-5	2021	Tranexamic acid (TXA), which is an anti-inflammatory medicine that inhibits plasmin, reduces the level of PGE2 secreted following UV exposure or after inflammatory stimulation.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	76-83
33196514-12	2021	Despite decreased fibrinogen levels after on-pump CABG with tranexamic acid, fibrin clot susceptibility to lysis is impaired, as reflected by prolonged CLT.	Tranexamic Acid	60-75	fibrinogen beta chain	Homo sapiens	18-28
34035635-4	2021	Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	75-82
34035635-4	2021	Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	122-129
34035635-4	2021	Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	122-129
34035635-4	2021	Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin.	Tranexamic Acid	171-186	plasminogen	Homo sapiens	75-82
34035635-4	2021	Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin.	Tranexamic Acid	171-186	plasminogen	Homo sapiens	122-129
34035635-4	2021	Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin.	Tranexamic Acid	171-186	plasminogen	Homo sapiens	122-129
33001565-2	2021	TXA inhibits plasmin(ogen) binding to fibrin and reduces fibrinolysis.	Tranexamic Acid	0-3	plasminogen	Homo sapiens	13-20
33001565-12	2021	For all doses of TXA administered intravenously, the PG assay detected delayed time-to-peak (<=3 hours) and reduced the velocity, peak, and endogenous plasmin potential (<=24 hours) in plasma samples obtained post-infusion.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	151-158
33406059-5	2020	This article reviews a variety of options that are available to aid in caring for patients who refuse blood transfusions, ranging from tranexamic acid to erythropoiesis-stimulating agents.	Tranexamic Acid	135-150	activation induced cytidine deaminase	Homo sapiens	64-67
33463413-0	2021	Intravenous tranexamic acid is associated with safe reduced blood loss and transfusion rate in one-stage exchange for infected hip arthroplasty.	Tranexamic Acid	12-27	hedgehog interacting protein	Homo sapiens	127-130
33463413-1	2021	OBJECTIVES: This study aims to investigate if the use of intravenous (IV) tranexamic acid (TXA) during one-stage exchange for periprosthetic joint infection (PJI) of the hip that necessitates an extensive debridement is associated with decreased blood loss, if the rate of blood transfusion that may lead to side effects can be lowered with IV TXA, and if there is any difference regarding the occurrence of postoperative venous thromboembolism (VTE).	Tranexamic Acid	74-89	hedgehog interacting protein	Homo sapiens	170-173
33463413-1	2021	OBJECTIVES: This study aims to investigate if the use of intravenous (IV) tranexamic acid (TXA) during one-stage exchange for periprosthetic joint infection (PJI) of the hip that necessitates an extensive debridement is associated with decreased blood loss, if the rate of blood transfusion that may lead to side effects can be lowered with IV TXA, and if there is any difference regarding the occurrence of postoperative venous thromboembolism (VTE).	Tranexamic Acid	91-94	hedgehog interacting protein	Homo sapiens	170-173
33376415-9	2020	In addition, administration of tranexamic acid decreased the concentrations of interleukin (IL)-1beta and tumor necrosis factor-alpha, while it increased the levels of IL-10 and transforming growth factor-alpha in the brain.	Tranexamic Acid	31-46	interleukin 1 alpha	Mus musculus	79-101
33376415-9	2020	In addition, administration of tranexamic acid decreased the concentrations of interleukin (IL)-1beta and tumor necrosis factor-alpha, while it increased the levels of IL-10 and transforming growth factor-alpha in the brain.	Tranexamic Acid	31-46	tumor necrosis factor	Mus musculus	106-133
33376415-9	2020	In addition, administration of tranexamic acid decreased the concentrations of interleukin (IL)-1beta and tumor necrosis factor-alpha, while it increased the levels of IL-10 and transforming growth factor-alpha in the brain.	Tranexamic Acid	31-46	interleukin 10	Mus musculus	168-173
33376415-9	2020	In addition, administration of tranexamic acid decreased the concentrations of interleukin (IL)-1beta and tumor necrosis factor-alpha, while it increased the levels of IL-10 and transforming growth factor-alpha in the brain.	Tranexamic Acid	31-46	transforming growth factor alpha	Mus musculus	178-210
32732500-2	2020	Tranexamic acid (TXA) has recently been used to treat bleeding in trauma by preventing plasmin generation to limit fibrinolysis.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	87-94
32732500-2	2020	Tranexamic acid (TXA) has recently been used to treat bleeding in trauma by preventing plasmin generation to limit fibrinolysis.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	87-94
33230046-0	2020	Plasmin thrombelastography rapidly identifies trauma patients at risk for massive transfusion, mortality, and hyperfibrinolysis: A diagnostic tool to resolve an international debate on tranexamic acid?	Tranexamic Acid	185-200	plasminogen	Homo sapiens	0-7
33262252-20	2021	This is consistent with the results of the CRASH-3 trial which found that TXA reduced head injury death in patients with at least one reactive pupil at baseline.	Tranexamic Acid	74-77	asparaginase and isoaspartyl peptidase 1	Homo sapiens	43-48
33045195-6	2020	RESULTS: Women with HA that responded to leptin treatment have higher circulating levels/peak values of Inhibin A, Estradiol (E2), higher LH/FSH ratio and a trend to lower AMH compared with non-responders.	Tranexamic Acid	172-175	leptin	Homo sapiens	41-47
33269854-0	2020	[Efficacy and safety of tranexamic acid in total hip arthroplasty via direct anterior approach].	Tranexamic Acid	24-39	hedgehog interacting protein	Homo sapiens	49-52
33269854-1	2020	OBJECTIVE: To evaluate the efficacy and safety of local application of tranexamic acid (TXA) in reducing perioperative blood loss in total hip arthroplasty via direct anterior approach (DAA).	Tranexamic Acid	71-86	hedgehog interacting protein	Homo sapiens	139-142
33269854-1	2020	OBJECTIVE: To evaluate the efficacy and safety of local application of tranexamic acid (TXA) in reducing perioperative blood loss in total hip arthroplasty via direct anterior approach (DAA).	Tranexamic Acid	88-91	hedgehog interacting protein	Homo sapiens	139-142
33269854-14	2020	CONCLUSION: local application of tranexamic acid in total hip arthroplasty through direct anterior approach can safely and effectively reduce perioperative blood loss, and does not increase the risk of thrombosis, and does not affect the normal recovery of joint function.	Tranexamic Acid	33-48	hedgehog interacting protein	Homo sapiens	58-61
33212896-1	2020	Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., epsilon-aminocaproic acid and tranexamic acid); however, they have adverse side effects.	Tranexamic Acid	228-243	plasminogen activator, tissue type	Homo sapiens	162-165
33208180-2	2020	Tranexamic acid (TXA) reversibly blocks lysine binding sites on plasminogen molecules and inhibits plasmin formation.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	64-71
33208180-2	2020	Tranexamic acid (TXA) reversibly blocks lysine binding sites on plasminogen molecules and inhibits plasmin formation.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	64-71
32668057-10	2020	Since TXA can promote a pro-fibrinolytic effect via u-PA, these sex-differences may be related to brain u-PA levels.	Tranexamic Acid	6-9	plasminogen activator, urokinase	Mus musculus	52-56
32567734-2	2020	Tranexamic acid, a plasmin inhibitor, has demonstrated hypopigmenting properties.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	19-26
33126380-2	2020	The aim of the present study was to compare the efficacy and safety of oral TXA with intravenous TXA in patients undergoing total hip arthroplasty and total knee arthroplasty in a systematic review and meta-analysis.	Tranexamic Acid	76-79	hedgehog interacting protein	Homo sapiens	130-133
33126380-3	2020	METHODS: We conducted a meta-analysis to identify randomized controlled trials (RCTs) involving oral and intravenous TXA in total hip arthroplasty and total knee arthroplasty up to December 2019 by searching databases including PubMed, Web of Science, Embase, the Cochrane Controlled Trials Register, the Cochrane Library China Biology Medicine, China National Knowledge Infrastructure, China Science and Technology Journal Database and Wanfang.	Tranexamic Acid	117-120	hedgehog interacting protein	Homo sapiens	130-133
33023637-0	2020	The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial.	Tranexamic Acid	28-43	hedgehog interacting protein	Homo sapiens	82-85
33023637-1	2020	BACKGROUND: Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown.	Tranexamic Acid	17-32	hedgehog interacting protein	Homo sapiens	112-115
33023637-1	2020	BACKGROUND: Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown.	Tranexamic Acid	34-37	hedgehog interacting protein	Homo sapiens	112-115
32701529-2	2020	Tranexamic acid (TXA) prevents ultraviolet radiation induced pigmentation in melasma through interfering with the plasminogen-plasmin pathway.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	114-121
32701529-2	2020	Tranexamic acid (TXA) prevents ultraviolet radiation induced pigmentation in melasma through interfering with the plasminogen-plasmin pathway.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	114-121
33136959-0	2020	Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe?	Tranexamic Acid	0-15	WAPL cohesin release factor	Homo sapiens	65-68
32668057-10	2020	Since TXA can promote a pro-fibrinolytic effect via u-PA, these sex-differences may be related to brain u-PA levels.	Tranexamic Acid	6-9	plasminogen activator, urokinase	Mus musculus	104-108
32350188-2	2020	The clinical randomization of an antifibrinolytic in significant head injury (CRASH) -2 and CRASH-3 trials confirmed that tranexamic acid (TXA) was effective after trauma.	Tranexamic Acid	122-137	asparaginase and isoaspartyl peptidase 1	Homo sapiens	78-83
32350188-2	2020	The clinical randomization of an antifibrinolytic in significant head injury (CRASH) -2 and CRASH-3 trials confirmed that tranexamic acid (TXA) was effective after trauma.	Tranexamic Acid	122-137	asparaginase and isoaspartyl peptidase 1	Homo sapiens	92-97
33013880-10	2020	Neutrophil CD62L expression was reduced in the 4 g TXA group [fold change: 0.73 (0.63-0.97)] compared to the placebo group [0.97 (0.78-1.10)] at 24 h post-TXA (p = 0.034).	Tranexamic Acid	51-54	selectin L	Homo sapiens	11-16
33013880-10	2020	Neutrophil CD62L expression was reduced in the 4 g TXA group [fold change: 0.73 (0.63-0.97)] compared to the placebo group [0.97 (0.78-1.10)] at 24 h post-TXA (p = 0.034).	Tranexamic Acid	155-158	selectin L	Homo sapiens	11-16
33013880-11	2020	The fold decrease in plasma IL-6 was significantly less in the 4 g TXA group [1.36 (0.87-2.42)] compared to the placebo group [0.46 (0.19-1.69)] at 72 h post-TXA (p = 0.028).	Tranexamic Acid	67-70	interleukin 6	Homo sapiens	28-32
33013880-11	2020	The fold decrease in plasma IL-6 was significantly less in the 4 g TXA group [1.36 (0.87-2.42)] compared to the placebo group [0.46 (0.19-1.69)] at 72 h post-TXA (p = 0.028).	Tranexamic Acid	158-161	interleukin 6	Homo sapiens	28-32
32926708-0	2020	A Case Report of Nebulized Tranexamic Acid for Post-tonsillectomy Hemorrhage in an Adult.	Tranexamic Acid	27-42	solute carrier family 35 member G1	Homo sapiens	47-51
32908455-3	2020	Moreover, TXA has been approved as second-line prophylactic therapy for hereditary angioedema and further data have been published about a possible use of TXA as maintenance treatment for nonhistaminergic angioedema and treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors.	Tranexamic Acid	155-158	kininogen 1	Homo sapiens	246-256
32908455-3	2020	Moreover, TXA has been approved as second-line prophylactic therapy for hereditary angioedema and further data have been published about a possible use of TXA as maintenance treatment for nonhistaminergic angioedema and treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors.	Tranexamic Acid	155-158	angiotensin I converting enzyme	Homo sapiens	288-291
32881765-0	2020	Early Tranexamic Acid Administration After Traumatic Brain Injury Is Associated With Reduced Syndecan-1 and Angiopoietin-2 in Patients With Traumatic Intracranial Hemorrhage.	Tranexamic Acid	6-21	syndecan 1	Homo sapiens	93-103
32881765-0	2020	Early Tranexamic Acid Administration After Traumatic Brain Injury Is Associated With Reduced Syndecan-1 and Angiopoietin-2 in Patients With Traumatic Intracranial Hemorrhage.	Tranexamic Acid	6-21	angiopoietin 2	Homo sapiens	108-122
32881765-11	2020	Levels of syndecan-1 were lower in the TXA group (median [interquartile range or IQR] = 254.6 pg/mL [200.7-322.0] vs 272.4 pg/mL [219.7-373.1], P = .05.	Tranexamic Acid	39-42	syndecan 1	Homo sapiens	10-20
32881765-12	2020	Patients who received TXA less than 45 minutes postinjury had significantly lower levels of angiopoietin-2 (median [IQR] = 144.3 pg/mL [94.0-174.3] vs 154.6 pg/mL [110.4-209.8], P = .05).	Tranexamic Acid	22-25	angiopoietin 2	Homo sapiens	92-106
32881765-14	2020	CONCLUSIONS: TXA may inhibit early upregulation of syndecan-1 and angiopoietin-2 in patients with MS-TBI, suggesting attenuation of protease-mediated vascular glycocalyx breakdown.	Tranexamic Acid	13-16	syndecan 1	Homo sapiens	51-61
32881765-14	2020	CONCLUSIONS: TXA may inhibit early upregulation of syndecan-1 and angiopoietin-2 in patients with MS-TBI, suggesting attenuation of protease-mediated vascular glycocalyx breakdown.	Tranexamic Acid	13-16	angiopoietin 2	Homo sapiens	66-80
32954969-0	2020	Comparison between epsilon-aminocaproic acid and tranexamic acid for total hip and knee arthroplasty: A meta-analysis.	Tranexamic Acid	49-64	hedgehog interacting protein	Homo sapiens	75-78
32985369-0	2020	Intravenous administration of tranexamic acid in total hip arthroplasty does not change the blood coagulopathy: a prospective thrombelastography analysis.	Tranexamic Acid	30-45	hedgehog interacting protein	Homo sapiens	55-58
32985369-1	2020	OBJECTIVE: Despite the wide use of tranexamic acid (TXA) in the perioperative period of total hip arthroplasty (THA), whether the hemostatic state changes after the application of intravenous (IV)-TXA are still unknown.	Tranexamic Acid	35-50	hedgehog interacting protein	Homo sapiens	94-97
32985369-1	2020	OBJECTIVE: Despite the wide use of tranexamic acid (TXA) in the perioperative period of total hip arthroplasty (THA), whether the hemostatic state changes after the application of intravenous (IV)-TXA are still unknown.	Tranexamic Acid	52-55	hedgehog interacting protein	Homo sapiens	94-97
32926708-6	2020	CONCLUSION: To our knowledge, this is the first case in the emergency medicine literature that describes the use of nebulized TXA in an adult to achieve hemostasis in post-tonsillectomy hemorrhage.	Tranexamic Acid	126-129	solute carrier family 35 member G1	Homo sapiens	167-171
32418856-5	2020	Tranexamic acid (TXA) is effective for reducing surgery-related bleeding and effusions in total hip or knee arthroplasty.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	96-99
33329827-0	2020	Effects of tranexamic acid on the activity of glutamate transporter EAAT3.	Tranexamic Acid	11-26	solute carrier family 1 member 1	Homo sapiens	68-73
33329827-4	2020	Therefore, the authors investigated the effects of TXA on the activity of glutamate transporter type 3 (excitatory amino acid transporter 3; EAAT3), which is the main neuronal glutamate transporter type.	Tranexamic Acid	51-54	solute carrier family 1 member 1	Homo sapiens	74-139
33329827-4	2020	Therefore, the authors investigated the effects of TXA on the activity of glutamate transporter type 3 (excitatory amino acid transporter 3; EAAT3), which is the main neuronal glutamate transporter type.	Tranexamic Acid	51-54	solute carrier family 1 member 1	Homo sapiens	141-146
33329827-9	2020	Results: TXA (30 to 1,000 microM) significantly decreased EAAT3 activity.	Tranexamic Acid	9-12	solute carrier family 1 member 1	Homo sapiens	58-63
33329827-11	2020	Conclusions: Our results suggest that TXA attenuates EAAT3 activity, which may explain its proconvulsant effect.	Tranexamic Acid	38-41	solute carrier family 1 member 1	Homo sapiens	53-58
32898374-0	2020	Effectiveness of administering tranexamic acid to high-risk hip and knee arthroplasty patients: a systematic review protocol.	Tranexamic Acid	31-46	hedgehog interacting protein	Homo sapiens	60-63
32898374-1	2020	OBJECTIVE: The objective of this review is to assess the safety and effectiveness in administering tranexamic acid in high-risk hip and knee arthroplasty patients.	Tranexamic Acid	99-114	hedgehog interacting protein	Homo sapiens	128-131
32418856-5	2020	Tranexamic acid (TXA) is effective for reducing surgery-related bleeding and effusions in total hip or knee arthroplasty.	Tranexamic Acid	17-20	hedgehog interacting protein	Homo sapiens	96-99
32347005-6	2020	RESULTS: The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively.	Tranexamic Acid	51-54	C-reactive protein	Homo sapiens	13-16
31820035-0	2020	Is tranexamic acid going to CRASH the management of traumatic brain injury?	Tranexamic Acid	3-18	asparaginase and isoaspartyl peptidase 1	Homo sapiens	28-33
32347005-6	2020	RESULTS: The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively.	Tranexamic Acid	51-54	interleukin 6	Homo sapiens	21-25
31855889-0	2020	Tranexamic acid in traumatic intracranial bleeding: recognizing the limit of results (of the CRASH-3 trial).	Tranexamic Acid	0-15	asparaginase and isoaspartyl peptidase 1	Homo sapiens	93-98
31930602-9	2020	Blocking 12-HETE and TXA2 synthesis, or antagonism of the TXA2 receptor significantly reduced platelet aggregation enhanced by GPR91 signalling.	Tranexamic Acid	58-62	succinate receptor 1	Homo sapiens	127-132
32308543-4	2020	VEGF165 also promoted tyrosine phosphorylation of VEGFR-1 and VEGFR-2 in HUVECs, which was again abolished by TA.	Tranexamic Acid	110-112	fms related receptor tyrosine kinase 1	Homo sapiens	50-57
32259146-9	2020	Conclusion: The administration of TXA (loading dose of 1000 mg and continuous infusion of 100 mg h-1) reduced postoperative transfusion and perioperative blood loss.	Tranexamic Acid	34-37	H1.5 linker histone, cluster member	Homo sapiens	97-100
32308543-4	2020	VEGF165 also promoted tyrosine phosphorylation of VEGFR-1 and VEGFR-2 in HUVECs, which was again abolished by TA.	Tranexamic Acid	110-112	kinase insert domain receptor	Homo sapiens	62-69
32308543-5	2020	TA further showed similar effects to neutralization of VEGFR-1 and VEGFR-2 in inhibiting cell proliferation, migration, invasion and tube formation of HUVECs induced by VEGF165, suggesting that TA could inhibit angiogenesis by targeting VEGFRs in HUVECs.	Tranexamic Acid	194-196	fms related receptor tyrosine kinase 1	Homo sapiens	55-62
32308543-5	2020	TA further showed similar effects to neutralization of VEGFR-1 and VEGFR-2 in inhibiting cell proliferation, migration, invasion and tube formation of HUVECs induced by VEGF165, suggesting that TA could inhibit angiogenesis by targeting VEGFRs in HUVECs.	Tranexamic Acid	194-196	kinase insert domain receptor	Homo sapiens	67-74
32308543-6	2020	In addition, VEGF165 enhanced the expression of VEGFRs and promoted tyrosine phosphorylation of VEGFR-1 and VEGFR-2 in normal human melanocytes, which were also attenuated by TA.	Tranexamic Acid	175-177	fms related receptor tyrosine kinase 1	Homo sapiens	96-103
32308543-6	2020	In addition, VEGF165 enhanced the expression of VEGFRs and promoted tyrosine phosphorylation of VEGFR-1 and VEGFR-2 in normal human melanocytes, which were also attenuated by TA.	Tranexamic Acid	175-177	kinase insert domain receptor	Homo sapiens	108-115
32308543-7	2020	Furthermore, TA showed similar effects to neutralization of VEGFR-1 and VEGFR-2 in inhibiting tyrosinase activity, melanin production and even melanogenic proteins induced by VEGF165, suggesting that TA could reduce melanogenesis via inhibiting activation of VEGFRs and subsequent expression of melanogenic proteins in melanocytes.	Tranexamic Acid	13-15	tyrosinase	Homo sapiens	94-104
32308543-7	2020	Furthermore, TA showed similar effects to neutralization of VEGFR-1 and VEGFR-2 in inhibiting tyrosinase activity, melanin production and even melanogenic proteins induced by VEGF165, suggesting that TA could reduce melanogenesis via inhibiting activation of VEGFRs and subsequent expression of melanogenic proteins in melanocytes.	Tranexamic Acid	200-202	fms related receptor tyrosine kinase 1	Homo sapiens	60-67
31782901-10	2020	In FVIII-KO mice, blood loss after tail clip was lower after prophylaxis with rFVIII+TXA compared to rFVIII, with no statistical significance (p=0,15).	Tranexamic Acid	85-88	coagulation factor VIII	Mus musculus	3-8
32001608-10	2020	The finding that tPA and subsequent clot breakdown (illustrated by D-dimer formation) are raised in a broad range of patients, with little correlation between the initial fibrinolytic response and markers of injury severity, may be the reason that TXA is effective across a broad range of injured patients.	Tranexamic Acid	248-251	plasminogen activator, tissue type	Homo sapiens	17-20
32399109-12	2020	Conclusions: Increased BMI, low Fbg, and simultaneous bilateral TKA could act as risk factors for postoperative symptomatic VTE treated with TXA.	Tranexamic Acid	141-144	fibrinogen beta chain	Homo sapiens	32-35
32016928-10	2020	Fibrinogen levels were higher in the TXA group at 24 hours.	Tranexamic Acid	37-40	fibrinogen beta chain	Homo sapiens	0-10
31658420-5	2020	Furthermore, four types of promising active site inhibitors of plasmin have been developed: tranexamic acid conjugates targeting the S1 pocket and primed sites, substrate-analogue linear homopiperidylalanine-containing 4-amidinobenzylamide derivatives, macrocyclic inhibitors addressing nonprimed binding regions, and bicyclic 14-mer SFTI-1 analogues blocking both, primed and nonprimed binding sites of plasmin.	Tranexamic Acid	92-107	plasminogen	Homo sapiens	63-70
32118541-13	2020	CONCLUSION: IV TXA was effective in reducing allogeneic blood component transfusion (PRBCs and PT- or INR-guided FFP transfusion), without increasing the incidence of postoperative death or thrombotic complications in off-pump CAB surgery.	Tranexamic Acid	15-18	neural proliferation, differentiation and control 1	Homo sapiens	227-230
31678452-9	2020	At 1, 2, and 3 months, the residual hematoma volume was significantly smaller in the tranexamic acid group than in the other two groups.	Tranexamic Acid	85-100	angiotensin II receptor type 1	Homo sapiens	0-14
31604031-6	2020	This pathoadaptive response can be mitigated with the PLG inhibitor tranexamic acid (TXA) in a fashion that prevented clinically significant complications in validated murine models of both E. faecalis- and P. aeruginosa mediated colonic perforation.	Tranexamic Acid	68-83	plasminogen	Mus musculus	54-57
33146607-0	2020	[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?] Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events.	Tranexamic Acid	78-93	SLAM family member 8	Homo sapiens	97-103
33146607-0	2020	[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?] Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events.	Tranexamic Acid	105-120	hedgehog interacting protein	Homo sapiens	33-36
33146607-0	2020	[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?] Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events.	Tranexamic Acid	105-120	SLAM family member 8	Homo sapiens	97-103
33146607-0	2020	[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?] Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events.	Tranexamic Acid	122-125	hedgehog interacting protein	Homo sapiens	33-36
33146607-0	2020	[Acute Limb Ischemia after Total Hip Arthroplasty in a High-Risk Patient - Is Tranexamic Acid to Blame?] Tranexamic acid (TXA) is widely used to limit the blood loss during total joint arthroplasty without an increased risk of thromboembolic events.	Tranexamic Acid	122-125	SLAM family member 8	Homo sapiens	97-103
31604031-6	2020	This pathoadaptive response can be mitigated with the PLG inhibitor tranexamic acid (TXA) in a fashion that prevented clinically significant complications in validated murine models of both E. faecalis- and P. aeruginosa mediated colonic perforation.	Tranexamic Acid	85-88	plasminogen	Mus musculus	54-57
31929250-3	2020	Aims: The aim of the present study was to compare the effectiveness of tranexamic acid and epsilon-amino-caproic acid with respect to postoperative bleeding at 4 and 24 hours as the primary outcome, and rate of postoperative transfusion, re-operations, complication rate, serum fibrinogen, and D-dimer levels as secondary outcomes.	Tranexamic Acid	71-86	fibrinogen beta chain	Homo sapiens	278-288
31743119-4	2020	Tranexamic acid was administered for menorrhagia and resumed later for labor and continued into the postpartum period since antifibrinolytics have been the mainstay in the management of PAI-1 deficiency.	Tranexamic Acid	0-15	serpin family E member 1	Homo sapiens	186-191
31929250-12	2020	Bleeding at 24 hours was significantly lesser in tranexamic acid group as compared to epsilon-amino-caproic acid group, 350 ml (130-520) vs 430 ml (160-730) (P = 0.0022) The rate of transfusion, re-operations, seizures, renal dysfunction, fibrinogen levels, and D-dimer levels did not show significant difference between the groups.	Tranexamic Acid	49-64	fibrinogen beta chain	Homo sapiens	239-249
31894349-6	2021	Higher effect was observed by combination of fibrinogen with tranexamic acid and prothrombin complex with tranexamic acid, whereas the maximal effect was achieved using all agents together.	Tranexamic Acid	106-121	fibrinogen beta chain	Homo sapiens	45-55
31848266-0	2020	BET 1: Does inhaled tranexamic acid reduce morbidity in adults with haemoptysis?	Tranexamic Acid	20-35	Bet1 golgi vesicular membrane trafficking protein	Homo sapiens	0-5
32819728-1	2020	INTRODUCTION: Tranexamic Acid (TXA), an antifibrinolytic that inhibits the fibrinolytic activity of plasmin is used to decrease perioperative blood loss and transfusion requirements in orthopedic surgery.	Tranexamic Acid	14-29	plasminogen	Homo sapiens	100-107
32819728-1	2020	INTRODUCTION: Tranexamic Acid (TXA), an antifibrinolytic that inhibits the fibrinolytic activity of plasmin is used to decrease perioperative blood loss and transfusion requirements in orthopedic surgery.	Tranexamic Acid	31-34	plasminogen	Homo sapiens	100-107
31894349-6	2021	Higher effect was observed by combination of fibrinogen with tranexamic acid and prothrombin complex with tranexamic acid, whereas the maximal effect was achieved using all agents together.	Tranexamic Acid	106-121	coagulation factor II, thrombin	Homo sapiens	81-92
32962576-15	2020	CONCLUSION: Tranexamic acid has positive effect in early period of tendon healing by stimulating the TNF-alpha and MMP-3 expression levels.	Tranexamic Acid	12-27	tumor necrosis factor	Rattus norvegicus	101-110
32962576-0	2020	Tranexamic acid has positive effect in early period of tendon healing by stimulating the tumor necrosis factor-alpha and matrix metalloproteinase-3 expression levels.	Tranexamic Acid	0-15	tumor necrosis factor	Rattus norvegicus	89-116
32962576-15	2020	CONCLUSION: Tranexamic acid has positive effect in early period of tendon healing by stimulating the TNF-alpha and MMP-3 expression levels.	Tranexamic Acid	12-27	matrix metallopeptidase 3	Rattus norvegicus	115-120
32962576-0	2020	Tranexamic acid has positive effect in early period of tendon healing by stimulating the tumor necrosis factor-alpha and matrix metalloproteinase-3 expression levels.	Tranexamic Acid	0-15	matrix metallopeptidase 3	Rattus norvegicus	121-147
32064426-2	2020	Conversely, tranexamic acid (TXA) functions by inhibiting the conversion of plasminogen to plasmin, which inhibits fibrinolysis.	Tranexamic Acid	12-27	plasminogen	Homo sapiens	76-83
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	tumor necrosis factor	Rattus norvegicus	150-177
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	tumor necrosis factor	Rattus norvegicus	179-188
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	matrix metallopeptidase 3	Rattus norvegicus	191-217
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	matrix metallopeptidase 3	Rattus norvegicus	219-224
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	transforming growth factor alpha	Rattus norvegicus	264-272
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	tumor necrosis factor	Rattus norvegicus	305-314
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	matrix metallopeptidase 3	Rattus norvegicus	316-321
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	54-69	transforming growth factor alpha	Rattus norvegicus	327-335
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	tumor necrosis factor	Rattus norvegicus	150-177
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	matrix metallopeptidase 3	Rattus norvegicus	191-217
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	matrix metallopeptidase 3	Rattus norvegicus	219-224
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	transforming growth factor alpha	Rattus norvegicus	264-272
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	tumor necrosis factor	Rattus norvegicus	305-314
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	matrix metallopeptidase 3	Rattus norvegicus	316-321
32962576-1	2020	OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-beta) expression; and to identify if TNF-alpha, MMP-3, and TGF-beta can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons.	Tranexamic Acid	71-74	transforming growth factor alpha	Rattus norvegicus	327-335
32962576-11	2020	Overall scores of TNF-alpha showed that TXA groups had significantly higher scores when compared to SP groups (p<0.05).	Tranexamic Acid	40-43	tumor necrosis factor	Rattus norvegicus	18-27
32962576-12	2020	In addition, total MMP-3 expression scores were significantly higher in TXA groups than in SP groups, respectively; TXA3: 14, TXA6: 11, SP3: 10, and SP6: 9 (p<0.05).	Tranexamic Acid	72-75	matrix metallopeptidase 3	Rattus norvegicus	19-24
32064426-2	2020	Conversely, tranexamic acid (TXA) functions by inhibiting the conversion of plasminogen to plasmin, which inhibits fibrinolysis.	Tranexamic Acid	29-32	plasminogen	Homo sapiens	76-83
31886224-11	2019	The TXA group also demonstrated a lower level of CRP on POD1 (p=0.02) and lower levels of CRP and serum D-dimer on POD3 (p=0.008 and p < 0.001).	Tranexamic Acid	4-7	C-reactive protein	Homo sapiens	49-52
31886224-11	2019	The TXA group also demonstrated a lower level of CRP on POD1 (p=0.02) and lower levels of CRP and serum D-dimer on POD3 (p=0.008 and p < 0.001).	Tranexamic Acid	4-7	C-reactive protein	Homo sapiens	90-93
31851007-1	2021	OBJECTIVE: To investigate the role of bacterial- mediated plasminogen (PLG) activation in the pathogenesis of anastomotic leak (AL) and its mitigation by tranexamic acid (TXA).	Tranexamic Acid	154-169	plasminogen	Mus musculus	71-74
31851007-9	2021	TXA inhibited PLG activation and downstream collagenolysis by pathogens known to have a causal role in AL.	Tranexamic Acid	0-3	plasminogen	Mus musculus	14-17
31851007-10	2021	TXA enema reduced collagenolytic bacteria counts and PLG deposition at anastomotic sites.	Tranexamic Acid	0-3	plasminogen	Mus musculus	53-56
31851007-11	2021	Postoperative PLG inhibition with TXA enema prevented clinically and pathologically apparent pathogen-mediated AL in mice.	Tranexamic Acid	34-37	plasminogen	Mus musculus	14-17
31749860-12	2019	5 of 6 patients were successfully treated with C1 INH or tranexamic acid for acute treatment of attacks (4 with C1 INH and 1 with tranexamic acid).	Tranexamic Acid	57-72	serpin family G member 1	Homo sapiens	112-118
31393041-8	2019	Wild-type mice treated with TXA also displayed increased cellularity of the cLN 1 week post TBI together with increases in innate and adaptive immune cells.	Tranexamic Acid	28-31	palmitoyl-protein thioesterase 1	Mus musculus	76-81
31236768-7	2019	Moreover, the blood level of tumor necrosis factor-alpha, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration.	Tranexamic Acid	158-173	tumor necrosis factor	Mus musculus	29-56
31236768-7	2019	Moreover, the blood level of tumor necrosis factor-alpha, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration.	Tranexamic Acid	158-173	interleukin 6	Mus musculus	58-71
31236768-7	2019	Moreover, the blood level of tumor necrosis factor-alpha, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration.	Tranexamic Acid	158-173	matrix metallopeptidase 9	Mus musculus	108-140
31236768-8	2019	These results indicate that tranexamic acid suppresses the secretion of inflammatory cytokines, MMP-9, and ROS induced by natural aging, ameliorating age-related diseases, and, consequently, extending the lifespan.	Tranexamic Acid	28-43	matrix metallopeptidase 9	Mus musculus	96-101
31749860-12	2019	5 of 6 patients were successfully treated with C1 INH or tranexamic acid for acute treatment of attacks (4 with C1 INH and 1 with tranexamic acid).	Tranexamic Acid	130-145	serpin family G member 1	Homo sapiens	47-53
31335970-7	2019	Tranexamic acid depressed fibrinolysis to a similar extent in FVIII-def and FIX-def plasmas.	Tranexamic Acid	0-15	coagulation factor VIII	Homo sapiens	62-67
32767875-2	2019	The use of Tranexamic Acid (ATX) is one of the methods used to decrease that bleeding.	Tranexamic Acid	11-26	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	28-31
31335970-7	2019	Tranexamic acid depressed fibrinolysis to a similar extent in FVIII-def and FIX-def plasmas.	Tranexamic Acid	0-15	UTP25 small subunit processome component	Homo sapiens	68-71
31335970-7	2019	Tranexamic acid depressed fibrinolysis to a similar extent in FVIII-def and FIX-def plasmas.	Tranexamic Acid	0-15	UTP25 small subunit processome component	Homo sapiens	80-83
31736753-2	2019	In human platelets, TXA2 is the major arachidonic acid derivative via the cyclooxygenase (COX)-1 pathway.	Tranexamic Acid	20-24	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	74-96
31481049-0	2019	Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	54-57
31115109-1	2019	OBJECTIVES: To investigate if supplementation with fibrinogen concentrate to blood samples collected after tranexamic acid administration improve clot formation more than what can be achieved with fibrinogen in the absence of tranexamic acid.	Tranexamic Acid	107-122	fibrinogen beta chain	Homo sapiens	51-61
31481049-8	2019	RESULTS: Usage of TXA can decrease not only the perioperative blood loss (p = 0.001), transfusion rate (p = 0.017) and supplemental amount of FVIII (p < 0.001) but also swelling ratio, surgical joint pain.	Tranexamic Acid	18-21	coagulation factor VIII	Homo sapiens	142-147
31489276-1	2019	Tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits plasminogen activation by binding to its lysine receptor sites and preventing its conversion to plasmin.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	66-73
31147768-9	2019	These results indicate that natural skin aging was ameliorated by tranexamic acid via the regulation of the plasmin/TGF-beta/epidermal cells/hyaluronic acid and plasmin/MMPs/ECM signal transmission pathways.	Tranexamic Acid	66-81	transforming growth factor alpha	Mus musculus	116-124
31489276-1	2019	Tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits plasminogen activation by binding to its lysine receptor sites and preventing its conversion to plasmin.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	66-73
31126915-1	2019	Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	63-70
31358003-0	2019	Tranexamic acid reduces heme cytotoxicity via the TLR4/TNF axis and ameliorates functional recovery after spinal cord injury.	Tranexamic Acid	0-15	toll-like receptor 4	Mus musculus	50-54
31358003-0	2019	Tranexamic acid reduces heme cytotoxicity via the TLR4/TNF axis and ameliorates functional recovery after spinal cord injury.	Tranexamic Acid	0-15	tumor necrosis factor	Mus musculus	55-58
31358003-13	2019	In TXA-treated SCI mice, the decreased expressions of TLR4 and TNF were observed at the lesion sites, accompanied by a significant reduction in the number of apoptotic cells and better functional recovery in comparison to saline-treated control mice.	Tranexamic Acid	3-6	toll-like receptor 4	Mus musculus	54-58
31358003-13	2019	In TXA-treated SCI mice, the decreased expressions of TLR4 and TNF were observed at the lesion sites, accompanied by a significant reduction in the number of apoptotic cells and better functional recovery in comparison to saline-treated control mice.	Tranexamic Acid	3-6	tumor necrosis factor	Mus musculus	63-66
31358003-14	2019	CONCLUSION: The administration of TXA ameliorated the intralesional cytotoxicity both by reducing the intralesional bleeding volume and preventing heme induction of the TLR4/TNF axis in the SCI lesion.	Tranexamic Acid	34-37	toll-like receptor 4	Mus musculus	169-173
31358003-14	2019	CONCLUSION: The administration of TXA ameliorated the intralesional cytotoxicity both by reducing the intralesional bleeding volume and preventing heme induction of the TLR4/TNF axis in the SCI lesion.	Tranexamic Acid	34-37	tumor necrosis factor	Mus musculus	174-177
31151207-8	2019	On the other hand, administration of tranexamic acid led to brown colored hair on gp91phox-/- mice.	Tranexamic Acid	37-52	cytochrome b-245, beta polypeptide	Mus musculus	82-93
31151207-9	2019	Although tranexamic acid treatment did not alter the expression levels of melanocortin receptor 1 and agouti signaling protein on hair follicles, it increased the expression of mahogunin ring finger protein 1 (MGRN1) and collagen XVII.	Tranexamic Acid	9-24	mahogunin, ring finger 1	Mus musculus	177-208
31151207-9	2019	Although tranexamic acid treatment did not alter the expression levels of melanocortin receptor 1 and agouti signaling protein on hair follicles, it increased the expression of mahogunin ring finger protein 1 (MGRN1) and collagen XVII.	Tranexamic Acid	9-24	mahogunin, ring finger 1	Mus musculus	210-215
31441836-9	2019	CONCLUSION: The combined administration of TXA + Dexa significantly reduced the level of postoperative CRP and IL-6, relieve postoperative pain, ameliorate the incidence of POVN, provide additional analgesic and antiemetic effects, reduce postoperative fatigue, and improve ROM, without increasing the risk of complications in primary TKA.	Tranexamic Acid	43-46	C-reactive protein	Homo sapiens	103-106
31441836-9	2019	CONCLUSION: The combined administration of TXA + Dexa significantly reduced the level of postoperative CRP and IL-6, relieve postoperative pain, ameliorate the incidence of POVN, provide additional analgesic and antiemetic effects, reduce postoperative fatigue, and improve ROM, without increasing the risk of complications in primary TKA.	Tranexamic Acid	43-46	interleukin 6	Homo sapiens	111-115
31126915-1	2019	Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	63-70
31126915-2	2019	Because plasmin is known to promote inflammatory and immunosuppressive responses, we explored the possibility that plasmin-mediated immunosuppression in patients undergoing cardiac surgery can be directly reversed by TXA and decrease postoperative infection rates.	Tranexamic Acid	217-220	plasminogen	Homo sapiens	115-122
31126915-9	2019	TXA was also shown to exert an immune-modulatory effect in healthy volunteers, further supporting the fibrin-independent effect of TXA on immune function and indicating that baseline plasmin levels contribute to the regulation of the immune system in the absence of any comorbidity or surgical trauma.	Tranexamic Acid	0-3	plasminogen	Homo sapiens	183-190
30988876-1	2019	Background/purpose: Tranexamic acid (TA) is one of the commonly used local hemostatic agents for dental procedures and a previous study has demonstrated a significantly lower incidence of post-procedural bleeding (PPB) in patients taking warfarin and received local TA treatment after the dental procedures than those who took warfarin and did not receive local TA treatment.	Tranexamic Acid	20-35	histatin 1	Homo sapiens	214-217
32246605-4	2019	The use of tranexamic acid (ATX) is quite widespread 71.9% of respondents (46/64).	Tranexamic Acid	11-26	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	28-31
31141852-2	2019	Tranexamic acid (TXA), a potent plasmin inhibitor, is proposed to control pigmentation by inhibiting the release of inflammatory mediators involved in triggering melanogenesis.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	32-39
31141852-2	2019	Tranexamic acid (TXA), a potent plasmin inhibitor, is proposed to control pigmentation by inhibiting the release of inflammatory mediators involved in triggering melanogenesis.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	32-39
30988876-1	2019	Background/purpose: Tranexamic acid (TA) is one of the commonly used local hemostatic agents for dental procedures and a previous study has demonstrated a significantly lower incidence of post-procedural bleeding (PPB) in patients taking warfarin and received local TA treatment after the dental procedures than those who took warfarin and did not receive local TA treatment.	Tranexamic Acid	37-39	histatin 1	Homo sapiens	214-217
30988876-6	2019	Results: The analysis revealed a higher risk of PPB in patients who took OAC and received local TA treatment after the dental procedures than individuals who did not take OAC and underwent similar dental procedures with the pooled OR of 2.4, although the pooled effect estimate had a relatively wide 95% CI with non-statistically difference (0.69-8.12).	Tranexamic Acid	96-98	histatin 1	Homo sapiens	48-51
30578968-8	2019	Furthermore, the anti-inflammatory effects of TXA were associated with the inhibition of TLR2, pro-inflammatory cytokines (IL-6 and TNFalpha) and chemokines (CCL10) expression in LL37-activated HaCaT cells.	Tranexamic Acid	46-49	toll like receptor 2	Homo sapiens	89-93
30267577-6	2019	Furthermore, tranexamic acid treatment was observed to suppress increases in the plasma levels of matrix metalloproteinase-9 and interleukin (IL)-6, and skin expression of plasmin, CC chemokine 2, macrophages, signal transducer and activator of transcription (STAT)3, cyclin D and vascular endothelial growth factor (VEGF)-A that occurred in mice subjected to long-term UVA irradiation.	Tranexamic Acid	13-28	signal transducer and activator of transcription 3	Mus musculus	210-266
30267577-6	2019	Furthermore, tranexamic acid treatment was observed to suppress increases in the plasma levels of matrix metalloproteinase-9 and interleukin (IL)-6, and skin expression of plasmin, CC chemokine 2, macrophages, signal transducer and activator of transcription (STAT)3, cyclin D and vascular endothelial growth factor (VEGF)-A that occurred in mice subjected to long-term UVA irradiation.	Tranexamic Acid	13-28	vascular endothelial growth factor A	Mus musculus	281-315
30267577-6	2019	Furthermore, tranexamic acid treatment was observed to suppress increases in the plasma levels of matrix metalloproteinase-9 and interleukin (IL)-6, and skin expression of plasmin, CC chemokine 2, macrophages, signal transducer and activator of transcription (STAT)3, cyclin D and vascular endothelial growth factor (VEGF)-A that occurred in mice subjected to long-term UVA irradiation.	Tranexamic Acid	13-28	vascular endothelial growth factor A	Mus musculus	317-321
30267577-7	2019	These results indicated that the nonmelanoma skin cancer induced by DMBA+UVA long-term irradiation is ameliorated by tranexamic acid through regulation of the plasmin/macrophage/IL-6/STAT3/cyclin D signal transmission pathway.	Tranexamic Acid	117-132	interleukin 6	Mus musculus	178-182
30267577-7	2019	These results indicated that the nonmelanoma skin cancer induced by DMBA+UVA long-term irradiation is ameliorated by tranexamic acid through regulation of the plasmin/macrophage/IL-6/STAT3/cyclin D signal transmission pathway.	Tranexamic Acid	117-132	signal transducer and activator of transcription 3	Mus musculus	183-188
30267577-6	2019	Furthermore, tranexamic acid treatment was observed to suppress increases in the plasma levels of matrix metalloproteinase-9 and interleukin (IL)-6, and skin expression of plasmin, CC chemokine 2, macrophages, signal transducer and activator of transcription (STAT)3, cyclin D and vascular endothelial growth factor (VEGF)-A that occurred in mice subjected to long-term UVA irradiation.	Tranexamic Acid	13-28	matrix metallopeptidase 9	Mus musculus	98-124
30267577-6	2019	Furthermore, tranexamic acid treatment was observed to suppress increases in the plasma levels of matrix metalloproteinase-9 and interleukin (IL)-6, and skin expression of plasmin, CC chemokine 2, macrophages, signal transducer and activator of transcription (STAT)3, cyclin D and vascular endothelial growth factor (VEGF)-A that occurred in mice subjected to long-term UVA irradiation.	Tranexamic Acid	13-28	interleukin 6	Mus musculus	129-147
30578968-8	2019	Furthermore, the anti-inflammatory effects of TXA were associated with the inhibition of TLR2, pro-inflammatory cytokines (IL-6 and TNFalpha) and chemokines (CCL10) expression in LL37-activated HaCaT cells.	Tranexamic Acid	46-49	interleukin 6	Homo sapiens	123-140
30578968-9	2019	Finally, TXA repressed the angiogenesis by reducing the number of CD31+ cell and downregulating the expression levels of VEGF in rosacea.	Tranexamic Acid	9-12	platelet and endothelial cell adhesion molecule 1	Homo sapiens	66-70
30578968-9	2019	Finally, TXA repressed the angiogenesis by reducing the number of CD31+ cell and downregulating the expression levels of VEGF in rosacea.	Tranexamic Acid	9-12	vascular endothelial growth factor A	Homo sapiens	121-125
30575685-10	2019	RESULTS: Plasmin-mediated fibrinolysis by tPA in clotted PPP led to an approximately threefold increase in C5a production (p < 0.0001), which was significantly inhibited by TXA (p < 0.001).	Tranexamic Acid	173-176	complement C5a receptor 1	Homo sapiens	107-110
30575685-0	2019	Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	108-119
30575685-2	2019	Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	66-73
30575685-2	2019	Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	107-114
30575685-2	2019	Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	66-73
30575685-2	2019	Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	107-114
30575685-4	2019	Because TXA does not block uPA-dependent plasmin generation from PLG and instead augments it, we hypothesized that administration of TXA could enhance or inhibit proinflammatory C5a formation in a PLG activator-dependent manner.	Tranexamic Acid	133-136	complement C5a receptor 1	Homo sapiens	178-181
30451372-0	2019	Increased urokinase and consumption of alpha2 -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay.	Tranexamic Acid	104-119	serpin family F member 2	Homo sapiens	39-58
30451372-3	2019	Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting.	Tranexamic Acid	12-27	plasminogen	Homo sapiens	37-44
30451372-6	2019	However, large clinical trials show TXA becomes ineffective or harmful if treatment is delayed beyond 3 h. The mechanism is unknown but urokinase plasminogen activator (uPA) has been implicated.	Tranexamic Acid	36-39	plasminogen activator, urokinase	Homo sapiens	136-167
30451372-6	2019	However, large clinical trials show TXA becomes ineffective or harmful if treatment is delayed beyond 3 h. The mechanism is unknown but urokinase plasminogen activator (uPA) has been implicated.	Tranexamic Acid	36-39	plasminogen activator, urokinase	Homo sapiens	169-172
30451372-10	2019	Results IC50 values for antifibrinolytic activity of TXA varied from < 10 to > 1000 mumol L-1 depending on the system, but good fibrin protection was observed in the presence of tPA, uPA and plasmin.	Tranexamic Acid	53-56	plasminogen	Homo sapiens	191-198
30451372-11	2019	However, in plasma or blood, active plasmin was generated by TXA + uPA (but not tPA) and coagulopathy developed leading to no or poor clot formation.	Tranexamic Acid	61-64	plasminogen	Homo sapiens	36-43
30451372-16	2019	Conclusions Tranexamic acid protects fibrin but stimulates uPA activity and slows inhibition of plasmin by alpha2 -antiplasmin.	Tranexamic Acid	12-27	plasminogen activator, urokinase	Homo sapiens	59-62
30451372-16	2019	Conclusions Tranexamic acid protects fibrin but stimulates uPA activity and slows inhibition of plasmin by alpha2 -antiplasmin.	Tranexamic Acid	12-27	plasminogen	Homo sapiens	96-103
30451372-16	2019	Conclusions Tranexamic acid protects fibrin but stimulates uPA activity and slows inhibition of plasmin by alpha2 -antiplasmin.	Tranexamic Acid	12-27	serpin family F member 2	Homo sapiens	107-126
30575685-4	2019	Because TXA does not block uPA-dependent plasmin generation from PLG and instead augments it, we hypothesized that administration of TXA could enhance or inhibit proinflammatory C5a formation in a PLG activator-dependent manner.	Tranexamic Acid	133-136	plasminogen	Homo sapiens	197-200
30575685-10	2019	RESULTS: Plasmin-mediated fibrinolysis by tPA in clotted PPP led to an approximately threefold increase in C5a production (p < 0.0001), which was significantly inhibited by TXA (p < 0.001).	Tranexamic Acid	173-176	plasminogen	Homo sapiens	9-16
30575685-11	2019	Paradoxically, when fibrinolysis was induced by uPA, TXA treatment led to further increases in C5a production beyond uPA alone (p < 0.0001).	Tranexamic Acid	53-56	plasminogen activator, urokinase	Homo sapiens	48-51
30575685-11	2019	Paradoxically, when fibrinolysis was induced by uPA, TXA treatment led to further increases in C5a production beyond uPA alone (p < 0.0001).	Tranexamic Acid	53-56	complement C5a receptor 1	Homo sapiens	95-98
30575685-11	2019	Paradoxically, when fibrinolysis was induced by uPA, TXA treatment led to further increases in C5a production beyond uPA alone (p < 0.0001).	Tranexamic Acid	53-56	plasminogen activator, urokinase	Homo sapiens	117-120
30575685-14	2019	CONCLUSIONS: Tranexamic acid administration can have proinflammatory or anti-inflammatory effects through regulating C5a generation by plasmin, depending on the predominating PLG activator.	Tranexamic Acid	13-28	complement C5a receptor 1	Homo sapiens	117-120
30451372-18	2019	Additional direct inhibition of plasmin by aprotinin may prevent development of coagulopathy and extend the useful time window of TXA treatment.	Tranexamic Acid	130-133	plasminogen	Homo sapiens	32-39
30575685-14	2019	CONCLUSIONS: Tranexamic acid administration can have proinflammatory or anti-inflammatory effects through regulating C5a generation by plasmin, depending on the predominating PLG activator.	Tranexamic Acid	13-28	plasminogen	Homo sapiens	135-142
30575685-14	2019	CONCLUSIONS: Tranexamic acid administration can have proinflammatory or anti-inflammatory effects through regulating C5a generation by plasmin, depending on the predominating PLG activator.	Tranexamic Acid	13-28	plasminogen	Homo sapiens	175-178
30575685-15	2019	Tranexamic acid may cause significant inflammatory C5a elevations in injured tissues by augmenting uPA-mediated plasmin generation in a fibrin-independent manner.	Tranexamic Acid	0-15	complement C5a receptor 1	Homo sapiens	51-54
30575685-15	2019	Tranexamic acid may cause significant inflammatory C5a elevations in injured tissues by augmenting uPA-mediated plasmin generation in a fibrin-independent manner.	Tranexamic Acid	0-15	plasminogen activator, urokinase	Homo sapiens	99-102
30575685-15	2019	Tranexamic acid may cause significant inflammatory C5a elevations in injured tissues by augmenting uPA-mediated plasmin generation in a fibrin-independent manner.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	112-119
30575685-16	2019	In contrast, TXA reduces C5a generation during tPA-mediated fibrinolysis that may reduce inflammatory responses.	Tranexamic Acid	13-16	complement C5a receptor 1	Homo sapiens	25-28
30640647-0	2019	Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	114-117
30640647-0	2019	Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society.	Tranexamic Acid	0-15	hedgehog interacting protein	Homo sapiens	238-241
30238726-11	2018	Univariate analysis showed that the level of IL-6 in serum at 1 day after operation was significantly higher in variables as follows: age, diagnosis, history of lung infection, range of motion, preoperative levels of CRP and IL-6 in serum, intravenous dosage of tranexamic acid and dexamethasone on day of operation ( P&lt;0.05).	Tranexamic Acid	262-277	interleukin 6	Homo sapiens	45-49
30496326-8	2018	Tranexamic acid treatment was associated with a significant decrease in serum IL-1beta at six and 24 hours and IL-10 at 24 hours from start of shock compared to vehicle control.	Tranexamic Acid	0-15	interleukin 1 beta	Rattus norvegicus	78-86
30496326-8	2018	Tranexamic acid treatment was associated with a significant decrease in serum IL-1beta at six and 24 hours and IL-10 at 24 hours from start of shock compared to vehicle control.	Tranexamic Acid	0-15	interleukin 10	Rattus norvegicus	111-116
29729197-6	2018	Importantly, administration of the pharmacological plasmin inhibitor tranexamic acid or genetic reduction of plasminogen, the circulating zymogen of plasmin, ameliorates APAP-induced hepatic fibronectin degradation and sinusoidal bleeding.	Tranexamic Acid	69-84	fibronectin 1	Mus musculus	191-202
30353092-0	2018	Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1.	Tranexamic Acid	0-15	coagulation factor II, thrombin	Homo sapiens	27-35
30353092-7	2018	Tranexamic acid, soybean trypsin inhibitor, or bivalirudin (a thrombin inhibitor) also reduced the calcium elevation induced by Cry j1 and/or thrombin.	Tranexamic Acid	0-15	coagulation factor II, thrombin	Homo sapiens	62-70
30353092-7	2018	Tranexamic acid, soybean trypsin inhibitor, or bivalirudin (a thrombin inhibitor) also reduced the calcium elevation induced by Cry j1 and/or thrombin.	Tranexamic Acid	0-15	coagulation factor II, thrombin	Homo sapiens	142-150
29926296-0	2018	The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis.	Tranexamic Acid	53-68	plasminogen	Homo sapiens	82-89
29735174-0	2018	[Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors].	Tranexamic Acid	1-16	kininogen 1	Homo sapiens	67-77
29735174-0	2018	[Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors].	Tranexamic Acid	1-16	angiotensin I converting enzyme	Homo sapiens	109-112
29735174-6	2018	The aim of this retrospective study is to assess the benefits of emergency tranexamic acid administration in the management of ACE inhibitor-induced episodes of angioedema.	Tranexamic Acid	75-90	angiotensin I converting enzyme	Homo sapiens	127-130
29735174-13	2018	CONCLUSION: Tranexamic acid is an easily accessible and affordable therapy that may provide effective treatment for ACE inhibitor-induced episodes of angioedema.	Tranexamic Acid	12-27	angiotensin I converting enzyme	Homo sapiens	116-119
30081203-5	2018	However, the increased levels of urocortin 2, methionine enkephalin, histamine, OGFR, T-bet, and GATA3 were suppressed by tranexamic acid treatment.	Tranexamic Acid	122-137	urocortin 2	Mus musculus	33-44
30081203-5	2018	However, the increased levels of urocortin 2, methionine enkephalin, histamine, OGFR, T-bet, and GATA3 were suppressed by tranexamic acid treatment.	Tranexamic Acid	122-137	opioid growth factor receptor	Mus musculus	80-84
30081203-5	2018	However, the increased levels of urocortin 2, methionine enkephalin, histamine, OGFR, T-bet, and GATA3 were suppressed by tranexamic acid treatment.	Tranexamic Acid	122-137	T-box 21	Mus musculus	86-91
30081203-5	2018	However, the increased levels of urocortin 2, methionine enkephalin, histamine, OGFR, T-bet, and GATA3 were suppressed by tranexamic acid treatment.	Tranexamic Acid	122-137	GATA binding protein 3	Mus musculus	97-102
30081203-6	2018	Conversely, the levels of beta-endorphin and mu-opioid receptor increased with tranexamic acid treatment.	Tranexamic Acid	79-94	pro-opiomelanocortin-alpha	Mus musculus	26-40
30081203-7	2018	In addition, the expression of the estrogen receptor-beta on the surface of mast cells was increased by tranexamic acid.	Tranexamic Acid	104-119	estrogen receptor 2 (beta)	Mus musculus	35-57
30081203-9	2018	Furthermore, this ameliorative effect on photoaging may be due to an increase in estrogen receptor-beta after tranexamic acid treatment.	Tranexamic Acid	110-125	estrogen receptor 2 (beta)	Mus musculus	81-103
33655140-1	2018	CONTEXT: The purpose of this study was to assess the effectiveness of topical pre-closure application of tranexamic acid (TXA) to reduce postoperative blood loss and blood transfusion rates in primary total hip and knee arthroplasty (THA and TKA) in a private, high-volume orthopedic specialty hospital setting.	Tranexamic Acid	105-120	hedgehog interacting protein	Homo sapiens	207-210
33655140-1	2018	CONTEXT: The purpose of this study was to assess the effectiveness of topical pre-closure application of tranexamic acid (TXA) to reduce postoperative blood loss and blood transfusion rates in primary total hip and knee arthroplasty (THA and TKA) in a private, high-volume orthopedic specialty hospital setting.	Tranexamic Acid	122-125	hedgehog interacting protein	Homo sapiens	207-210
30253023-1	2018	Tranexamic acid (TXA), a plasmin inhibitor, is an antifibrinolytic drug widely used to prevent and treat hemorrhage.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	25-32
30253023-1	2018	Tranexamic acid (TXA), a plasmin inhibitor, is an antifibrinolytic drug widely used to prevent and treat hemorrhage.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	25-32
29189568-11	2018	Furthermore, the levels of the prethrombosis-state molecular markers GMP-140, fibrinogen, fibrin degradation products, and D-dimer were higher in the TXA group than in the Placebo group, although the differences were not significant (P &gt; 0.05).	Tranexamic Acid	150-153	selectin P	Homo sapiens	69-76
30030237-0	2018	BET 1: Intravenous tranexamic acid for the treatment of post-partum haemorrhage.	Tranexamic Acid	19-34	Bet1 golgi vesicular membrane trafficking protein	Homo sapiens	0-5
29675813-5	2018	In addition, we simulate the efficacy of tranexamic acid treatment on coagulopathy initiated through endothelial t-PA release, and are able to reproduce the time-sensitive nature of the efficacy of this treatment as observed in clinical studies.	Tranexamic Acid	41-56	plasminogen activator, tissue type	Homo sapiens	113-117
29189568-11	2018	Furthermore, the levels of the prethrombosis-state molecular markers GMP-140, fibrinogen, fibrin degradation products, and D-dimer were higher in the TXA group than in the Placebo group, although the differences were not significant (P &gt; 0.05).	Tranexamic Acid	150-153	fibrinogen beta chain	Homo sapiens	78-88
29430682-12	2018	Treatment with TXA rescued the ENO1-induced reductions in TJ and TEER expression.	Tranexamic Acid	15-18	enolase 1	Homo sapiens	31-35
29914535-5	2018	RESULTS: After the bone cut and surgery, TXA significantly increased MCP-1, TNF-alpha, IL-1beta and IL-6 levels compared to non-TXA patients, which was further amplified postoperatively.	Tranexamic Acid	41-44	C-C motif chemokine ligand 2	Homo sapiens	69-74
29914535-5	2018	RESULTS: After the bone cut and surgery, TXA significantly increased MCP-1, TNF-alpha, IL-1beta and IL-6 levels compared to non-TXA patients, which was further amplified postoperatively.	Tranexamic Acid	41-44	tumor necrosis factor	Homo sapiens	76-85
29914535-5	2018	RESULTS: After the bone cut and surgery, TXA significantly increased MCP-1, TNF-alpha, IL-1beta and IL-6 levels compared to non-TXA patients, which was further amplified postoperatively.	Tranexamic Acid	41-44	interleukin 1 beta	Homo sapiens	87-95
29914535-5	2018	RESULTS: After the bone cut and surgery, TXA significantly increased MCP-1, TNF-alpha, IL-1beta and IL-6 levels compared to non-TXA patients, which was further amplified postoperatively.	Tranexamic Acid	41-44	interleukin 6	Homo sapiens	100-104
29715224-4	2018	The addition of tranexamic acid during a surgical procedure may mitigate the coagulopathy by impeding the derangement in D-dimer and fibrinogen kinetics.	Tranexamic Acid	16-31	fibrinogen beta chain	Homo sapiens	133-143
29715224-11	2018	The consumption of fibrinogen was 98.4 +- 42.6 mg/dL in the control cohort but was reduced in the tranexamic acid cohort to 60.6 +- 35.1 mg/dL (p = 0.004).	Tranexamic Acid	98-113	fibrinogen beta chain	Homo sapiens	19-29
29715224-13	2018	Monitoring of D-dimer and fibrinogen during spinal surgery suggests that tranexamic acid impedes the fibrinolytic pathway by decreasing consumption of fibrinogen and clot dissolution as evidenced by the reduced formation of D-dimer.	Tranexamic Acid	73-88	fibrinogen beta chain	Homo sapiens	26-36
29715224-13	2018	Monitoring of D-dimer and fibrinogen during spinal surgery suggests that tranexamic acid impedes the fibrinolytic pathway by decreasing consumption of fibrinogen and clot dissolution as evidenced by the reduced formation of D-dimer.	Tranexamic Acid	73-88	fibrinogen beta chain	Homo sapiens	151-161
29715236-2	2018	: "Effect of Tranexamic Acid on Blood Loss, D-Dimer, and Fibrinogen Kinetics in Adult Spinal Deformity Surgery".	Tranexamic Acid	13-28	fibrinogen beta chain	Homo sapiens	57-67
29498767-7	2018	Moreover, the results confirm that activation of MMP-1 depends on increased plasmin activity in this model and lattice miniaturization was inhibited by the plasmin inhibitor tranexamic acid.	Tranexamic Acid	174-189	matrix metallopeptidase 1	Homo sapiens	49-54
29498767-7	2018	Moreover, the results confirm that activation of MMP-1 depends on increased plasmin activity in this model and lattice miniaturization was inhibited by the plasmin inhibitor tranexamic acid.	Tranexamic Acid	174-189	plasminogen	Homo sapiens	76-83
29498767-7	2018	Moreover, the results confirm that activation of MMP-1 depends on increased plasmin activity in this model and lattice miniaturization was inhibited by the plasmin inhibitor tranexamic acid.	Tranexamic Acid	174-189	plasminogen	Homo sapiens	156-163
28678111-4	2018	TXA competitively inhibits plasmin and batroxobin converts fibrinogen to fibrin and theoretically their combination is synergistic.	Tranexamic Acid	0-3	plasminogen	Homo sapiens	27-34
29239953-12	2018	Production of fibrinogen fragments (represented by D-dimers) was significantly lower in the TXA group compared to group C. CONCLUSIONS: Early prehospital administration of TXA leads to clot stabilization and a reduction of fibrinolytic activity, causing a decrease in fibrin degradation products buildup (D-dimer).	Tranexamic Acid	92-95	fibrinogen beta chain	Homo sapiens	14-24
29462500-2	2018	Antifibrinolytics, primarily tranexamic acid (TXA), have been shown to reduce bleeding in surgery and safely reduces mortality in trauma patients with bleeding without increasing the risk of adverse events.An earlier Cochrane review on treatments for primary PPH covered all the various available treatments - that review has now been split by types of treatment.	Tranexamic Acid	29-44	enolase 1	Homo sapiens	259-262
29462500-2	2018	Antifibrinolytics, primarily tranexamic acid (TXA), have been shown to reduce bleeding in surgery and safely reduces mortality in trauma patients with bleeding without increasing the risk of adverse events.An earlier Cochrane review on treatments for primary PPH covered all the various available treatments - that review has now been split by types of treatment.	Tranexamic Acid	46-49	enolase 1	Homo sapiens	259-262
29239953-12	2018	Production of fibrinogen fragments (represented by D-dimers) was significantly lower in the TXA group compared to group C. CONCLUSIONS: Early prehospital administration of TXA leads to clot stabilization and a reduction of fibrinolytic activity, causing a decrease in fibrin degradation products buildup (D-dimer).	Tranexamic Acid	172-175	fibrinogen beta chain	Homo sapiens	14-24
29208367-11	2018	As shown in the Connectivity MAP analysis, transamin inhibited the invasiveness of EpCAM-silenced EC cells.	Tranexamic Acid	43-52	epithelial cell adhesion molecule	Homo sapiens	83-88
29193211-10	2018	The model-estimated time during which the TXA concentration was above 10 mg l-1 ranged from 3.3 h to 16.3 h. No relationship was found between blood loss and either the time during which the TXA concentration exceeded 10 mg l-1 or the other exposure markers tested (maximum plasma concentration, area under the concentration-time curve).	Tranexamic Acid	42-45	immunoglobulin kappa variable 1-16	Homo sapiens	76-79
29193211-11	2018	CONCLUSION: In hip arthroplasty, TXA plasma concentrations were maintained above 10 mg l-1 during surgery and for a minimum of 3 h with a preoperative TXA dose of 1 g. Keeping TXA concentrations above this threshold up to 16 h conferred no advantage with regard to blood loss.	Tranexamic Acid	33-36	immunoglobulin kappa variable 1-16	Homo sapiens	87-90
29306228-1	2017	The aim of this study is to examine the perioperative hemostatic effects of tranexamic acid (TnX-A) and desmopressin acetate (Des) in these patients.	Tranexamic Acid	76-91	tenascin XA (pseudogene)	Homo sapiens	93-96
29040203-8	2018	TXA was added at various times after hydrogen peroxide (H2O2) and/or EPI exposure.	Tranexamic Acid	0-3	tissue factor pathway inhibitor	Homo sapiens	69-72
29354728-1	2017	Background: Tranexamic acid is a synthetic lysine-analogue antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, it is a well-documented blood sparing agent.	Tranexamic Acid	12-27	plasminogen	Homo sapiens	122-129
29123986-13	2017	Tranexamic acid decreased galanin (1-20) and the hemoglobin content of tumors and suppressed tumor growth.	Tranexamic Acid	0-15	galanin and GMAP prepropeptide	Mus musculus	26-33
28914172-4	2017	Pre-administration of tranexamic acid (TXA), which is a competitive inhibitor of Plg binding, to hepatectomized rats mildly delayed restoration of liver weight in vivo.	Tranexamic Acid	22-37	plasminogen	Rattus norvegicus	81-84
28914172-4	2017	Pre-administration of tranexamic acid (TXA), which is a competitive inhibitor of Plg binding, to hepatectomized rats mildly delayed restoration of liver weight in vivo.	Tranexamic Acid	39-42	plasminogen	Rattus norvegicus	81-84
28914172-5	2017	Although binding of Plg to the cell membrane decreased following TXA administration, TXA showed little effect on hepatocyte proliferation in rats.	Tranexamic Acid	65-68	plasminogen	Rattus norvegicus	20-23
28601310-8	2017	Tranexamic acid (TXA) was added to inhibit plasmin-dependent fibrinolysis.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	43-50
27173008-2	2017	Tranexamic acid has been found to lighten melasma by interfering with the interaction of melanocytes and keratinocytes by inhibiting the plasminogen/plasmin system.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	137-144
28688660-13	2017	At 24 hours after TBI, mice given TXA demonstrated lower splenic total cell counts central memory CD8, effector CD8, B cell, and increased naive CD4 cell populations.	Tranexamic Acid	34-37	CD4 antigen	Mus musculus	145-148
28669590-8	2017	The direct effect of TXA-mediated autophagy activation on melanin production was further evaluated by transfecting the cells with 60 pmols of small interfering RNAs (siRNAs)-targeting the mechanistic target of rapamycin (mTOR) and the autophagy-related protein 5 (Atg5).	Tranexamic Acid	21-24	mechanistic target of rapamycin kinase	Mus musculus	188-219
28669590-8	2017	The direct effect of TXA-mediated autophagy activation on melanin production was further evaluated by transfecting the cells with 60 pmols of small interfering RNAs (siRNAs)-targeting the mechanistic target of rapamycin (mTOR) and the autophagy-related protein 5 (Atg5).	Tranexamic Acid	21-24	mechanistic target of rapamycin kinase	Mus musculus	221-225
28669590-8	2017	The direct effect of TXA-mediated autophagy activation on melanin production was further evaluated by transfecting the cells with 60 pmols of small interfering RNAs (siRNAs)-targeting the mechanistic target of rapamycin (mTOR) and the autophagy-related protein 5 (Atg5).	Tranexamic Acid	21-24	autophagy related 5	Mus musculus	235-262
28669590-8	2017	The direct effect of TXA-mediated autophagy activation on melanin production was further evaluated by transfecting the cells with 60 pmols of small interfering RNAs (siRNAs)-targeting the mechanistic target of rapamycin (mTOR) and the autophagy-related protein 5 (Atg5).	Tranexamic Acid	21-24	autophagy related 5	Mus musculus	264-268
28669590-9	2017	RESULTS: The results of Western blottings showed that TXA enhanced the production of autophagy-related proteins such as mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1/2, Beclin-1, Atg12, and light chain 3 (LC3) I-II, whereas it decreased the synthesis of the mTOR complex.	Tranexamic Acid	54-57	mitogen-activated protein kinase 3	Mus musculus	163-209
28669590-9	2017	RESULTS: The results of Western blottings showed that TXA enhanced the production of autophagy-related proteins such as mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1/2, Beclin-1, Atg12, and light chain 3 (LC3) I-II, whereas it decreased the synthesis of the mTOR complex.	Tranexamic Acid	54-57	beclin 1, autophagy related	Mus musculus	211-219
28669590-9	2017	RESULTS: The results of Western blottings showed that TXA enhanced the production of autophagy-related proteins such as mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1/2, Beclin-1, Atg12, and light chain 3 (LC3) I-II, whereas it decreased the synthesis of the mTOR complex.	Tranexamic Acid	54-57	autophagy related 12	Mus musculus	221-226
28669590-9	2017	RESULTS: The results of Western blottings showed that TXA enhanced the production of autophagy-related proteins such as mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1/2, Beclin-1, Atg12, and light chain 3 (LC3) I-II, whereas it decreased the synthesis of the mTOR complex.	Tranexamic Acid	54-57	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	247-250
28669590-9	2017	RESULTS: The results of Western blottings showed that TXA enhanced the production of autophagy-related proteins such as mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1/2, Beclin-1, Atg12, and light chain 3 (LC3) I-II, whereas it decreased the synthesis of the mTOR complex.	Tranexamic Acid	54-57	mechanistic target of rapamycin kinase	Mus musculus	300-304
28669590-10	2017	Confocal microscopy clearly showed that TXA treatment resulted in the formation of autophagosomes in B16-F1 cells, as revealed by immunostaining with an anti-LC3 antibody.	Tranexamic Acid	40-43	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	158-161
28669590-11	2017	The production of melanogenesis-associated proteins, including microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase-related protein 1 and 2 (TRP1/2), were clearly downregulated by the treatments with TXA.	Tranexamic Acid	229-232	melanogenesis associated transcription factor	Mus musculus	18-109
28669590-11	2017	The production of melanogenesis-associated proteins, including microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase-related protein 1 and 2 (TRP1/2), were clearly downregulated by the treatments with TXA.	Tranexamic Acid	229-232	melanogenesis associated transcription factor	Mus musculus	111-115
28669590-11	2017	The production of melanogenesis-associated proteins, including microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase-related protein 1 and 2 (TRP1/2), were clearly downregulated by the treatments with TXA.	Tranexamic Acid	229-232	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	134-168
28669590-11	2017	The production of melanogenesis-associated proteins, including microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase-related protein 1 and 2 (TRP1/2), were clearly downregulated by the treatments with TXA.	Tranexamic Acid	229-232	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	170-176
28669590-12	2017	These results suggest that TXA can mediate a decrease in melanin synthesis by alleviating the production of tyrosinase and TRP1/2, along with lowered MITF protein levels.	Tranexamic Acid	27-30	tyrosinase	Mus musculus	108-118
28669590-12	2017	These results suggest that TXA can mediate a decrease in melanin synthesis by alleviating the production of tyrosinase and TRP1/2, along with lowered MITF protein levels.	Tranexamic Acid	27-30	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	123-129
28669590-12	2017	These results suggest that TXA can mediate a decrease in melanin synthesis by alleviating the production of tyrosinase and TRP1/2, along with lowered MITF protein levels.	Tranexamic Acid	27-30	melanogenesis associated transcription factor	Mus musculus	150-154
28669590-13	2017	Furthermore, after treatment with TXA, siRNAs- targeting to mTOR and Atg5 increased melanin synthesis by 20% and 40%, respectively, compared to that in non-transfected cells, in a dose-dependent manner.	Tranexamic Acid	34-37	mechanistic target of rapamycin kinase	Mus musculus	60-64
28669590-13	2017	Furthermore, after treatment with TXA, siRNAs- targeting to mTOR and Atg5 increased melanin synthesis by 20% and 40%, respectively, compared to that in non-transfected cells, in a dose-dependent manner.	Tranexamic Acid	34-37	autophagy related 5	Mus musculus	69-73
28669590-15	2017	CONCLUSION: Collectively, the results demonstrate that TXA can reduce melanin synthesis in melanoma B16-F1 cells by activating the ERK signaling pathway and the autophagy system.	Tranexamic Acid	55-58	mitogen-activated protein kinase 1	Mus musculus	131-134
28601310-8	2017	Tranexamic acid (TXA) was added to inhibit plasmin-dependent fibrinolysis.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	43-50
28235177-0	2016	AANA Journal Course: Update for Nurse Anesthetists-Part 5-Use of Tranexamic Acid in Preventing Postpartum Hemorrhage.	Tranexamic Acid	65-80	tankyrase	Homo sapiens	51-57
28090594-14	2016	The primary outcome is the effect of TXA on thrombin generation.	Tranexamic Acid	37-40	coagulation factor II, thrombin	Homo sapiens	44-52
28413832-4	2016	TXA may have effects on thrombin generation, platelet function and coagulation factors as a result of its inhibition on the plasmin.	Tranexamic Acid	0-3	coagulation factor II, thrombin	Homo sapiens	24-32
28413832-16	2016	The data from this study will provide evidence for the effect of TXA on thrombin generation, platelet function and coagulation factors in women with PPH.	Tranexamic Acid	65-68	coagulation factor II, thrombin	Homo sapiens	72-80
29296720-0	2017	X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.	Tranexamic Acid	40-55	plasminogen	Homo sapiens	27-34
29296720-4	2017	Currently, tranexamic acid (TXA), a molecule that prevents plasminogen activation through blocking recruitment to target substrates, is the most widely used inhibitor for the plasminogen/plasmin system in therapeutics.	Tranexamic Acid	11-26	plasminogen	Homo sapiens	59-66
29296720-4	2017	Currently, tranexamic acid (TXA), a molecule that prevents plasminogen activation through blocking recruitment to target substrates, is the most widely used inhibitor for the plasminogen/plasmin system in therapeutics.	Tranexamic Acid	28-31	plasminogen	Homo sapiens	59-66
29296720-9	2017	Here, the TXA moiety of the YO compounds inserts into the primary (S1) specificity pocket, suggesting that TXA itself may function as a weak plasmin inhibitor, a hypothesis supported by subsequent biochemical and biophysical analyses.	Tranexamic Acid	10-13	plasminogen	Homo sapiens	141-148
29296720-9	2017	Here, the TXA moiety of the YO compounds inserts into the primary (S1) specificity pocket, suggesting that TXA itself may function as a weak plasmin inhibitor, a hypothesis supported by subsequent biochemical and biophysical analyses.	Tranexamic Acid	107-110	plasminogen	Homo sapiens	141-148
28319931-0	2016	BET 1: Tranexamic acid in epistaxis: who bloody nose?	Tranexamic Acid	7-22	Bet1 golgi vesicular membrane trafficking protein	Homo sapiens	0-5
27426220-9	2016	The mean hemoglobin delta was also significantly less for the TEA group (2.0 +- 1.3 g/dL) compared with the no-TEA group (3.5 +- 1.4 g/dL, P &lt; .0001).	Tranexamic Acid	62-65	hemoglobin subunit delta	Homo sapiens	9-25
27027557-4	2016	We therefore hypothesized that intraluminal TXA as a serine protease inhibitor would reduce intestinal sheddases and syndecan-1 shedding, mitigating gut and distant organ (lung) damage.	Tranexamic Acid	44-47	syndecan 1	Homo sapiens	117-127
27393926-5	2016	Furthermore, the level of beta-endorphin in the plasma and the expression of beta-endorphin, mu-opioid receptor, and macrophages in the dorsal skin increased after the administration of tranexamic acid, and this increase was higher in female mice than in males.	Tranexamic Acid	186-201	pro-opiomelanocortin-alpha	Mus musculus	26-40
27393926-5	2016	Furthermore, the level of beta-endorphin in the plasma and the expression of beta-endorphin, mu-opioid receptor, and macrophages in the dorsal skin increased after the administration of tranexamic acid, and this increase was higher in female mice than in males.	Tranexamic Acid	186-201	pro-opiomelanocortin-alpha	Mus musculus	77-91
27027557-10	2016	TXA reduced ADAM-17 and TNF-alpha, but not syndecan-1, in TXA-sham animals compared with sham vehicles.	Tranexamic Acid	0-3	ADAM metallopeptidase domain 17	Homo sapiens	12-19
27027557-10	2016	TXA reduced ADAM-17 and TNF-alpha, but not syndecan-1, in TXA-sham animals compared with sham vehicles.	Tranexamic Acid	0-3	tumor necrosis factor	Homo sapiens	24-33
27102553-1	2016	INTRODUCTION: This study aimed to evaluate whether the combination of erythropoietin (EPO) and tranexamic acid (TXA) exerted any additional benefits on the number of blood transfusions required and haematological parameters compared with TXA alone following primary bilateral simultaneous total hip arthroplasty.	Tranexamic Acid	238-241	erythropoietin	Homo sapiens	86-89
27102553-8	2016	RESULTS: The total amount of blood transfusion and mean blood transfusion per patient was lower in group EPO + TXA than in group TXA (p = 0.039, p = 0.023; respectively).	Tranexamic Acid	111-114	erythropoietin	Homo sapiens	105-108
26663237-7	2016	Following the administration of tranexamic acid, the female displayed increased blood levels of beta-endorphin and mu-opioid receptor and estradiol receptor beta expression in comparison with the male.	Tranexamic Acid	32-47	pro-opiomelanocortin-alpha	Mus musculus	96-110
27192476-2	2016	We hypothesized that human fibrinogen concentrate (FC) and prothrombin complex concentrate (PCC), administered as combined therapy with TXA, would provide additive effects for reducing blood loss in an animal trauma model.	Tranexamic Acid	136-139	fibrinogen beta chain	Homo sapiens	27-37
27133035-6	2016	Moreover, the increase in the beta-endorphin level in the blood and the expression of mu-opioid receptor on the surface of fibroblasts increased by tranexamic acid treatment.	Tranexamic Acid	148-163	pro-opiomelanocortin-alpha	Mus musculus	30-44
26786299-11	2016	The length of exposure to tranexamic acid treatment was significantly more prolonged in women whose estimated glomerular filtration rate remained &lt;15mL/min/1.73m(2) (7.1+-4.8 vs 2.9+-2.4 hours; P=0.03).	Tranexamic Acid	26-41	CD59 molecule (CD59 blood group)	Homo sapiens	155-160
26663237-9	2016	CONCLUSIONS: These results suggest that the suppression by tranexamic acid of the UVB-induced melanocyte activation (UVB sensitivity) is stronger in female mice than in male mice and that female hormones and beta-endorphin play an important role in this sex difference.	Tranexamic Acid	59-74	pro-opiomelanocortin-alpha	Mus musculus	208-222
26948304-0	2016	Tranexamic Acid for Prevention PPH: a Promising Drug But Today Only a Promising Drug.	Tranexamic Acid	0-15	enolase 1	Homo sapiens	31-34
26460335-12	2016	Percentage change in d-dimer and tPA showed significantly lower values in patients treated with TXA compared to the nontreated group.	Tranexamic Acid	96-99	chromosome 20 open reading frame 181	Homo sapiens	33-36
26861101-6	2016	We administered tranexamic acid early in the pregnancy, and the subchorionic hematoma diminished in size in accordance with the increase of her fibrinogen level.	Tranexamic Acid	16-31	fibrinogen beta chain	Homo sapiens	144-154
26683393-7	2016	Tissue plasminogen activator (tPA) was added to blood samples collected before and after TXA administration to confirm that the TXA inhibited fibrinolysis.	Tranexamic Acid	128-131	plasminogen activator, tissue type	Sus scrofa	0-28
26683393-11	2016	The tPA-induced fibrinolysis was inhibited in the blood from TXA-treated animals, yet in fibrinolysis sensitivity studies, human plasma was 30 times more sensitive to tPA-induced fibrinolysis than swine plasma.	Tranexamic Acid	61-64	plasminogen activator, tissue type	Homo sapiens	4-7
26683393-11	2016	The tPA-induced fibrinolysis was inhibited in the blood from TXA-treated animals, yet in fibrinolysis sensitivity studies, human plasma was 30 times more sensitive to tPA-induced fibrinolysis than swine plasma.	Tranexamic Acid	61-64	plasminogen activator, tissue type	Homo sapiens	167-170
26258658-0	2015	Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator induced hyperfibrinolysis in children with congenital heart disease: A prospective, controlled, in-vitro study.	Tranexamic Acid	10-25	plasminogen activator, tissue type	Homo sapiens	62-95
26598634-0	2015	BET 1: Intravenous tranexamic acid in the treatment of acute epistaxis.	Tranexamic Acid	19-34	Bet1 golgi vesicular membrane trafficking protein	Homo sapiens	0-5
26083991-12	2015	Although early FgDPs have a pronounced effect on blood clot formation in vitro and therefore may induce or enhance in vivo coagulopathy, the drop of fibrinogen concentration seen after CABG surgery (using tranexamic acid) is primarily caused by hemodilution.	Tranexamic Acid	205-220	fibrinogen beta chain	Homo sapiens	149-159
26449600-2	2015	The CRASH-2 trial demonstrated that early administration of tranexamic acid, ideally within 3 hours, can reduce mortality from trauma-associated bleeding by up to 32%.	Tranexamic Acid	60-75	asparaginase and isoaspartyl peptidase 1	Homo sapiens	4-9
26538719-2	2015	Tranexamic acid, a plasmin inhibitor, has demonstrated depigmenting properties and combining this oral drug with other modalities of treatment has shown promising results.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	19-26
25673638-6	2015	Tranexamic acid inhibited ICH expansion in uPA(-/-)mice but not in tPA(-/-) mice.	Tranexamic Acid	0-15	plasminogen activator, urokinase	Mus musculus	43-46
26177992-3	2015	Tranexamic acid (TA), a plasmin inhibitor, is reported to improve melasma when injected locally or used as oral and topical forms.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	24-31
26177992-3	2015	Tranexamic acid (TA), a plasmin inhibitor, is reported to improve melasma when injected locally or used as oral and topical forms.	Tranexamic Acid	17-19	plasminogen	Homo sapiens	24-31
25944790-9	2015	alpha-Enolase coprecipitated with PAR-2 and plasminogen/plasmin on HMVECs and PMNs and induced PMN priming, which was inhibited by tranexamic acid, and enzymatic activity was not required.	Tranexamic Acid	131-146	enolase 1	Homo sapiens	0-13
26082580-9	2015	RESULTS: Tranexamic acid-treated melanocytes exhibited reduced melanin content and tyrosinase activity.	Tranexamic Acid	9-24	tyrosinase	Homo sapiens	83-93
26082580-10	2015	Tranexamic acid also decreased tyrosinase, TRP-1, and TRP-2 protein levels.	Tranexamic Acid	0-15	tyrosinase	Homo sapiens	31-41
26082580-10	2015	Tranexamic acid also decreased tyrosinase, TRP-1, and TRP-2 protein levels.	Tranexamic Acid	0-15	tyrosinase related protein 1	Homo sapiens	43-48
26082580-10	2015	Tranexamic acid also decreased tyrosinase, TRP-1, and TRP-2 protein levels.	Tranexamic Acid	0-15	dopachrome tautomerase	Homo sapiens	54-59
25747626-1	2015	INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin.	Tranexamic Acid	14-29	plasminogen	Homo sapiens	105-112
25806960-8	2015	In the presence of TXA, t-PA-induced hyperfibrinolysis was completely abolished.	Tranexamic Acid	19-22	plasminogen activator, tissue type	Homo sapiens	24-28
25747626-1	2015	INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin.	Tranexamic Acid	31-34	plasminogen	Homo sapiens	105-112
25605262-1	2015	BET 1: tranexamic acid in life-threatening haematuria.	Tranexamic Acid	7-22	Bet1 golgi vesicular membrane trafficking protein	Homo sapiens	0-5
24967824-4	2015	The patients were instructed to dilute 1 ampulla of TXA in 300 ml of tap water (concentration 0.2%) from postoperative day 5-10 and to gargle or spray the tonsillar fossae 5-6 times daily.	Tranexamic Acid	52-55	nuclear RNA export factor 1	Homo sapiens	69-72
24659483-4	2014	Tranexamic acid and epsilon-aminocaproic acid, two small molecule plasmin inhibitors, are currently used in the clinic.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	66-73
26448897-0	2015	CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media.	Tranexamic Acid	17-32	asparaginase and isoaspartyl peptidase 1	Homo sapiens	0-5
26448897-2	2015	CRASH-2, a large randomized controlled trial, was the first to show a reduction in mortality and recommend tranexamic acid use in bleeding trauma patients.	Tranexamic Acid	107-122	asparaginase and isoaspartyl peptidase 1	Homo sapiens	0-5
25423534-0	2014	Tranexamic acid administration to pediatric trauma patients in a combat setting: the pediatric trauma and tranexamic acid study (PED-TRAX).	Tranexamic Acid	0-15	translin associated factor X	Homo sapiens	133-137
24756178-1	2015	INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin.	Tranexamic Acid	14-29	plasminogen	Homo sapiens	111-118
24756178-1	2015	INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin.	Tranexamic Acid	31-34	plasminogen	Homo sapiens	111-118
25056964-0	2014	Tranexamic acid suppresses ultraviolet B eye irradiation-induced melanocyte activation by decreasing the levels of prohormone convertase 2 and alpha-melanocyte-stimulating hormone.	Tranexamic Acid	0-15	proprotein convertase subtilisin/kexin type 2	Homo sapiens	115-138
25056964-0	2014	Tranexamic acid suppresses ultraviolet B eye irradiation-induced melanocyte activation by decreasing the levels of prohormone convertase 2 and alpha-melanocyte-stimulating hormone.	Tranexamic Acid	0-15	proopiomelanocortin	Homo sapiens	143-179
25056964-5	2014	The plasma alpha-melanocyte-stimulating hormone (alpha-MSH) content was increased by UVB irradiation of the eye; however, the increase in alpha-MSH was suppressed by tranexamic acid treatment.	Tranexamic Acid	166-181	proopiomelanocortin	Homo sapiens	11-47
25056964-5	2014	The plasma alpha-melanocyte-stimulating hormone (alpha-MSH) content was increased by UVB irradiation of the eye; however, the increase in alpha-MSH was suppressed by tranexamic acid treatment.	Tranexamic Acid	166-181	proopiomelanocortin	Homo sapiens	138-147
25056964-7	2014	Meanwhile, the increase in PC2 induced by UVB eye irradiation was suppressed by tranexamic acid treatment.	Tranexamic Acid	80-95	proprotein convertase subtilisin/kexin type 2	Homo sapiens	27-30
25056964-8	2014	CONCLUSIONS: These results clearly indicate that tranexamic acid decreases the expression of PC2, which cleavages from proopiomelanocortin to alpha-MSH in the pituitary gland, thereby suppressing melanocyte activation.	Tranexamic Acid	49-64	proprotein convertase subtilisin/kexin type 2	Homo sapiens	93-96
25056964-8	2014	CONCLUSIONS: These results clearly indicate that tranexamic acid decreases the expression of PC2, which cleavages from proopiomelanocortin to alpha-MSH in the pituitary gland, thereby suppressing melanocyte activation.	Tranexamic Acid	49-64	proopiomelanocortin	Homo sapiens	142-151
23967870-0	2014	Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin.	Tranexamic Acid	0-15	occludin	Homo sapiens	66-74
23967870-1	2014	BACKGROUND: Tranexamic acid (TA) is a traditional plasmin inhibitor, and its role in the renovation of damaged skin has become the topic of a lot of research.	Tranexamic Acid	12-27	plasminogen	Homo sapiens	50-57
23967870-1	2014	BACKGROUND: Tranexamic acid (TA) is a traditional plasmin inhibitor, and its role in the renovation of damaged skin has become the topic of a lot of research.	Tranexamic Acid	29-31	plasminogen	Homo sapiens	50-57
23967870-7	2014	CONCLUSION: These experiments suggest that TA can accelerate skin barrier recovery and upregulate occludin induced by physicochemical damages of human skin, but it is advisable to perform more research on the upregulation of occludin in molecular mechanism in the future.	Tranexamic Acid	43-45	occludin	Homo sapiens	98-106
23967870-7	2014	CONCLUSION: These experiments suggest that TA can accelerate skin barrier recovery and upregulate occludin induced by physicochemical damages of human skin, but it is advisable to perform more research on the upregulation of occludin in molecular mechanism in the future.	Tranexamic Acid	43-45	occludin	Homo sapiens	225-233
24883106-6	2014	At week 12, CRP increased in the 500 mg AMH (p = 0.003) and placebo (p = 0.012) groups from their BL levels but not in the 1000 mg group.	Tranexamic Acid	40-43	C-reactive protein	Homo sapiens	12-15
25392658-12	2014	Superoxide dismutase and glutathione S-transferase activities were found to be higher in the control group than in the TA group (P=.005) and HA/CMC group (P=.009).	Tranexamic Acid	119-121	hematopoietic prostaglandin D synthase	Rattus norvegicus	25-50
24846097-1	2014	BET 3: Topical intranasal tranexamic acid for spontaneous epistaxis.	Tranexamic Acid	26-41	trafficking protein particle complex subunit 3	Homo sapiens	0-5
24805256-8	2014	Matrix metalloproteinase (MMP) inhibitors (doxycycline, GM 6001), and serine protease inhibitor (tranexamic acid) in the lumen, significantly reduced the fluorescein transport compared to saline for 90 min of ischemia.	Tranexamic Acid	97-112	Serine protease inhibitor	Rattus norvegicus	70-95
24418941-6	2014	Time courses for tPA, fibrin monomers, and fibrinogen were also similar for both regimen, and there was a significant difference in tPA-PAI1 complex concentrations at the end of surgery, which may be related to a significantly higher tranexamic acid concentration.	Tranexamic Acid	234-249	chromosome 20 open reading frame 181	Homo sapiens	132-135
24418941-6	2014	Time courses for tPA, fibrin monomers, and fibrinogen were also similar for both regimen, and there was a significant difference in tPA-PAI1 complex concentrations at the end of surgery, which may be related to a significantly higher tranexamic acid concentration.	Tranexamic Acid	234-249	serpin family E member 1	Homo sapiens	136-140
24333477-8	2014	Finally, we examined the effects of an antagonist(s) that reduced tranexamic acid-induced kaolin intake on the increase in c-Fos immunoreactive cells.	Tranexamic Acid	66-81	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	123-128
24335749-10	2014	TXA at concentrations of 0.1, 0.3, 1, 5, or 10 mM led to a dose-dependent reduction of GABAA receptor-mediated currents in patch clamp recordings.	Tranexamic Acid	0-3	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	87-92
24335749-15	2014	Because GABAA receptor antagonists are known to promote epileptiform activity, this effect might explain the proconvulsant action of TXA.	Tranexamic Acid	133-136	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	8-13
24333477-11	2014	Tranexamic acid significantly increased c-Fos immunoreactive cells by approximately 5.5-fold and 22-fold in the area postrema and nucleus of solitary tract, respectively.	Tranexamic Acid	0-15	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-45
24126146-2	2014	Among other prevention methods, treatment with tranexamic acid (ATX) has shown to be effective in reducing surgical blood loss, especially in the immediate postoperative period.	Tranexamic Acid	47-62	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	64-67
23261456-6	2013	Furthermore, injection of tranexamic acid, a plasmin inhibitor, more markedly reduced MMP-9 and MMP-2 activity and angiogenesis in tumors originating from progalanin siRNA-treated SBC-3A cells and in tumor tissue originating from progalanin siRNA-treated SBC-3A cells in the presence of progalanin.	Tranexamic Acid	26-41	plasminogen	Homo sapiens	45-52
23052111-12	2013	CONCLUSION: The use of tranexamic acid could reduce acute blood loss significantly without any adverse effect resulted from drug interaction with concomitant use of indirect factor Xa inhibitor following TKA.	Tranexamic Acid	23-38	coagulation factor X	Homo sapiens	174-183
23661406-6	2013	In the UK, tranexamic acid, a tissue plasminogen and plasmin inhibitor, is most commonly used, with evidence for benefit in cardiac, orthopaedic, urological, gynaecological, and obstetric surgery.	Tranexamic Acid	11-26	plasminogen	Homo sapiens	37-44
23354242-0	2013	Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.	Tranexamic Acid	152-167	plasminogen activator, tissue type	Homo sapiens	12-45
22329442-2	2013	Tranexamic acid (TXA), a plasmin inhibitor, is reported to improve melasma when injected locally.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	25-32
22329442-2	2013	Tranexamic acid (TXA), a plasmin inhibitor, is reported to improve melasma when injected locally.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	25-32
23643001-1	2013	OBJECTIVE: To evaluate the influence of different tranexamic acid administration methods during and after cardiac surgery with cardiopulmonary bypass(CPB) on coagulation function and postoperative bleeding.	Tranexamic Acid	50-65	carboxypeptidase B1	Homo sapiens	150-153
23360261-0	2013	A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.	Tranexamic Acid	121-136	coagulation factor II, thrombin	Homo sapiens	199-207
23360261-0	2013	A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.	Tranexamic Acid	121-136	coagulation factor X	Homo sapiens	212-215
23261456-6	2013	Furthermore, injection of tranexamic acid, a plasmin inhibitor, more markedly reduced MMP-9 and MMP-2 activity and angiogenesis in tumors originating from progalanin siRNA-treated SBC-3A cells and in tumor tissue originating from progalanin siRNA-treated SBC-3A cells in the presence of progalanin.	Tranexamic Acid	26-41	matrix metallopeptidase 9	Homo sapiens	86-91
23261456-6	2013	Furthermore, injection of tranexamic acid, a plasmin inhibitor, more markedly reduced MMP-9 and MMP-2 activity and angiogenesis in tumors originating from progalanin siRNA-treated SBC-3A cells and in tumor tissue originating from progalanin siRNA-treated SBC-3A cells in the presence of progalanin.	Tranexamic Acid	26-41	matrix metallopeptidase 2	Homo sapiens	96-101
23261456-7	2013	The reduction of MMP-9 and MMP-2 activity with tranexamic acid was restored by galanin, but not by progalanin.	Tranexamic Acid	47-62	matrix metallopeptidase 9	Homo sapiens	17-22
23261456-7	2013	The reduction of MMP-9 and MMP-2 activity with tranexamic acid was restored by galanin, but not by progalanin.	Tranexamic Acid	47-62	matrix metallopeptidase 2	Homo sapiens	27-32
21358317-3	2011	We hypothesized that intraoperative TXA would reduce blood transfusion relative to placebo in patients pretreated with erythropoietin.	Tranexamic Acid	36-39	erythropoietin	Homo sapiens	119-133
23249729-8	2013	When icatibant was compared to tranexamic acid in FAST-2, the median time to clinically significant relief of the index symptom was shorter for patients receiving icatibant (p &lt; 0.001).	Tranexamic Acid	31-46	forkhead box H1	Homo sapiens	50-56
22918041-7	2012	Treating of blood with tranexamic acid (60 mmol/l) was followed by decreased fibrinolytic potential of both exogenous tPA and uPA, despite uPA by itself is known to be not sensitive to aminocaproic acids.	Tranexamic Acid	23-38	plasminogen activator, tissue type	Homo sapiens	118-121
22918041-7	2012	Treating of blood with tranexamic acid (60 mmol/l) was followed by decreased fibrinolytic potential of both exogenous tPA and uPA, despite uPA by itself is known to be not sensitive to aminocaproic acids.	Tranexamic Acid	23-38	plasminogen activator, urokinase	Homo sapiens	126-129
22918041-7	2012	Treating of blood with tranexamic acid (60 mmol/l) was followed by decreased fibrinolytic potential of both exogenous tPA and uPA, despite uPA by itself is known to be not sensitive to aminocaproic acids.	Tranexamic Acid	23-38	plasminogen activator, urokinase	Homo sapiens	139-142
22827564-4	2012	Mean plasma tranexamic acid concentrations during the intra-operative period and in the first 6 postoperative hours were consistently higher than the suggested threshold to achieve 100% inhibition and 80% inhibition of tissue plasminogen activator.	Tranexamic Acid	12-27	chromosome 20 open reading frame 181	Homo sapiens	219-247
22974122-6	2012	Urokinase plasminogen activator (u-PA)-catalyzed fibrinolysis was also inhibited by TA, even though Pgn activation could be stimulated.	Tranexamic Acid	84-86	plasminogen activator, urokinase	Homo sapiens	0-31
22974122-6	2012	Urokinase plasminogen activator (u-PA)-catalyzed fibrinolysis was also inhibited by TA, even though Pgn activation could be stimulated.	Tranexamic Acid	84-86	plasminogen activator, urokinase	Homo sapiens	33-37
22903425-0	2012	BET 1: should tranexamic acid be given to patients who are having an upper gastrointestinal bleed?	Tranexamic Acid	14-29	Bet1 golgi vesicular membrane trafficking protein	Homo sapiens	0-5
22542983-9	2012	DISCUSSION: Tranexamic acid associated to direct anti-Xa (antithrombin-independent) oral anticoagulants was effective in reducing postoperative blood loss, improving hemoglobinemia at 5 days and reducing transfusion rates.	Tranexamic Acid	12-27	serpin family C member 1	Homo sapiens	58-70
21903703-0	2011	Ischaemic stroke following tranexamic acid in young patients carrying heterozygosity of MTHFR C677T.	Tranexamic Acid	27-42	methylenetetrahydrofolate reductase	Homo sapiens	88-93
22197274-9	2012	Tranexamic acid or virally inactivated fresh frozen plasma can be used for long-term prophylaxis if human plasma-derived C1-INH is not available.	Tranexamic Acid	0-15	serpin family G member 1	Homo sapiens	121-127
21707521-10	2011	In addition, tranexamic acid, a plasmin inhibitor, inhibited progalanin conversion to galanin(1-20).	Tranexamic Acid	13-28	plasminogen	Homo sapiens	32-39
21371192-0	2011	Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.	Tranexamic Acid	79-94	coagulation factor VIII	Homo sapiens	98-103
21371192-2	2011	In this study we tested whether the combination of plasma derived activated prothrombin complex concentrate (pd-aPCC) with tranexamic acid (TXA) may improve fibrin clot stability in FVIII inhibitor plasma.	Tranexamic Acid	123-138	coagulation factor VIII	Homo sapiens	182-187
21371192-2	2011	In this study we tested whether the combination of plasma derived activated prothrombin complex concentrate (pd-aPCC) with tranexamic acid (TXA) may improve fibrin clot stability in FVIII inhibitor plasma.	Tranexamic Acid	140-143	coagulation factor VIII	Homo sapiens	182-187
21371192-10	2011	Our results suggest that the combination of pd-aPCC with TXA improves clot stability in FVIII inhibitor plasma without additional increases in thrombin generation.	Tranexamic Acid	57-60	coagulation factor VIII	Homo sapiens	88-93
19886924-0	2010	Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema.	Tranexamic Acid	12-27	kininogen 1	Homo sapiens	51-61
21039598-9	2011	Plasma-derived C1-INH was used by 44 patients to treat a total of 376 acute attacks that resolved faster (1.1 day) than those not treated (1.85 day) or treated with tranexamic acid (1.79 day).	Tranexamic Acid	165-180	serpin family G member 1	Homo sapiens	15-21
19207486-9	2009	RESULTS: Tranexamic acid alone and in combination with CTT1 can inhibit tongue SCC invasion in vitro, at least partially explained by its property of reducing the plasmin-mediated activation of proMMP-9.	Tranexamic Acid	9-24	serpin family B member 3	Homo sapiens	79-82
20494037-6	2010	RESULTS: Tumor necrosis factor-alpha increased initially after CPB in both the aprotinin and TXA groups, but at 24 and 48 hours post-CPB was approximately 50% lower in the aprotinin group (p &lt; 0.05).	Tranexamic Acid	93-96	tumor necrosis factor	Homo sapiens	9-36
20494037-7	2010	The IL-10 levels were threefold higher in the TXA group compared with the aprotinin group immediately post-CBP (p &lt; 0.05).	Tranexamic Acid	46-49	interleukin 10	Homo sapiens	4-9
20494037-8	2010	Plasma levels of MMP types associated with inflammation, MMP-8, and MMP-9, were twofold higher in the late post-CPB period in the TXA group when compared with the aprotinin group.	Tranexamic Acid	130-133	matrix metallopeptidase 8	Homo sapiens	17-20
20494037-8	2010	Plasma levels of MMP types associated with inflammation, MMP-8, and MMP-9, were twofold higher in the late post-CPB period in the TXA group when compared with the aprotinin group.	Tranexamic Acid	130-133	matrix metallopeptidase 8	Homo sapiens	57-62
20494037-8	2010	Plasma levels of MMP types associated with inflammation, MMP-8, and MMP-9, were twofold higher in the late post-CPB period in the TXA group when compared with the aprotinin group.	Tranexamic Acid	130-133	matrix metallopeptidase 9	Homo sapiens	68-73
20216063-3	2010	The value of fibrinogen concentrate and prohemostatic drugs such as tranexamic acid and recombinant factor VIIa is also pointed out.	Tranexamic Acid	68-83	fibrinogen beta chain	Homo sapiens	13-23
20185649-0	2010	Temporally and regionally disparate differences in plasmin activity by tranexamic acid.	Tranexamic Acid	71-86	plasminogen	Homo sapiens	51-58
20185649-2	2010	Improving coagulation by inhibiting fibrinolysis, primarily through inhibition of plasmin activity (PLact) with antifibrinolytics such as tranexamic acid (TXA), has been a pharmacological mainstay in cardiac surgical patients.	Tranexamic Acid	138-153	plasminogen	Homo sapiens	82-89
20185649-2	2010	Improving coagulation by inhibiting fibrinolysis, primarily through inhibition of plasmin activity (PLact) with antifibrinolytics such as tranexamic acid (TXA), has been a pharmacological mainstay in cardiac surgical patients.	Tranexamic Acid	155-158	plasminogen	Homo sapiens	82-89
19889106-5	2010	Overexpression of urokinase plasminogen activator and therefore of plasmin, was blocked by tranexamic acid (TA) in transduced HSC.	Tranexamic Acid	91-106	plasminogen activator, urokinase	Rattus norvegicus	18-49
19889106-5	2010	Overexpression of urokinase plasminogen activator and therefore of plasmin, was blocked by tranexamic acid (TA) in transduced HSC.	Tranexamic Acid	108-110	plasminogen activator, urokinase	Rattus norvegicus	18-49
19967165-0	2009	Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired alpha2-antiplasmin deficiency associated with AL amyloidosis.	Tranexamic Acid	23-38	serpin family F member 2	Homo sapiens	113-131
19207486-9	2009	RESULTS: Tranexamic acid alone and in combination with CTT1 can inhibit tongue SCC invasion in vitro, at least partially explained by its property of reducing the plasmin-mediated activation of proMMP-9.	Tranexamic Acid	9-24	plasminogen	Homo sapiens	163-170
19104179-9	2009	RESULTS: With its high affinity for plasmin (Ki, 2 nM), CU-2010 inhibited fibrinolysis comparable to aprotinin (Ki, 4 nM) and was ten times more potent than tranexamic acid.	Tranexamic Acid	157-172	plasminogen	Homo sapiens	36-43
17917247-9	2007	When HB or cytochrome C was treated with a range of serine proteases in the presence of various amines (Py4, N-(2-pyridyl)-1,3-diaminopropane, tranexamic acid, isonicotinic acid hydrazide and ampicillin), the modified peptide was detected in all cases tested, thus suggesting that amine modification widely accompanies digestion by proteases.	Tranexamic Acid	143-158	cytochrome c, somatic	Homo sapiens	11-23
18633013-7	2008	In contrast to modified thrombelastography, thrombin receptor-mediated aggregometry after CPB was significantly decreased only in those patients receiving tranexamic acid until the end of the study period in comparison to the aprotinin group (P &lt; 0.05).	Tranexamic Acid	155-170	coagulation factor II, thrombin	Homo sapiens	44-52
18695719-6	2008	Unspecific inhibition of the activity of ACE, a key enzyme of the renin-angiotensin system, in the presence of 6-AHA and t-AMCHA ([I]50 10.0 +/- 0.5 and 7.5 +/- 0.4 mM, respectively) was found.	Tranexamic Acid	121-128	angiotensin I converting enzyme	Homo sapiens	41-44
18460030-13	2008	The addition of aprotinin, a serine proteinase inhibitor, and tranexamic acid, a uPA-plasmin inhibitor, inhibited the plasmin-induced impairment of BM assembly and facilitated BM reorganization, thereby improving the epidermal structure.	Tranexamic Acid	62-77	plasminogen activator, urokinase	Homo sapiens	81-84
18460030-13	2008	The addition of aprotinin, a serine proteinase inhibitor, and tranexamic acid, a uPA-plasmin inhibitor, inhibited the plasmin-induced impairment of BM assembly and facilitated BM reorganization, thereby improving the epidermal structure.	Tranexamic Acid	62-77	plasminogen	Homo sapiens	85-92
18460030-13	2008	The addition of aprotinin, a serine proteinase inhibitor, and tranexamic acid, a uPA-plasmin inhibitor, inhibited the plasmin-induced impairment of BM assembly and facilitated BM reorganization, thereby improving the epidermal structure.	Tranexamic Acid	62-77	plasminogen	Homo sapiens	118-125
17541016-9	2007	Administration of the plasminogen inhibitor, tranexamic acid, reduced eosinophil and lymphocyte numbers, mucus production, and collagen deposition in the lungs of ovalbumin-treated Plg(+/+) mice.	Tranexamic Acid	45-60	plasminogen	Mus musculus	22-33
17541016-9	2007	Administration of the plasminogen inhibitor, tranexamic acid, reduced eosinophil and lymphocyte numbers, mucus production, and collagen deposition in the lungs of ovalbumin-treated Plg(+/+) mice.	Tranexamic Acid	45-60	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	163-172
17541016-9	2007	Administration of the plasminogen inhibitor, tranexamic acid, reduced eosinophil and lymphocyte numbers, mucus production, and collagen deposition in the lungs of ovalbumin-treated Plg(+/+) mice.	Tranexamic Acid	45-60	plasminogen	Mus musculus	181-184
17264955-0	2007	Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.	Tranexamic Acid	22-37	secretory leukocyte peptidase inhibitor	Homo sapiens	101-106
17264955-0	2007	Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.	Tranexamic Acid	22-37	endoglin	Homo sapiens	107-115
16258002-7	2005	Most importantly, addition of TXA or active PAI-1 almost completely eliminates the restorative effects of GSH on collagen degradation in TGF-beta treated cells.	Tranexamic Acid	30-33	transforming growth factor, beta 1	Mus musculus	137-145
16857898-4	2006	ACE and Sca-1 were expressed on 61% and 55% of AMCA(+)CD45(-)CD31(-) cells, respectively, and coexpressed on 38%.	Tranexamic Acid	47-51	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	0-3
16857898-4	2006	ACE and Sca-1 were expressed on 61% and 55% of AMCA(+)CD45(-)CD31(-) cells, respectively, and coexpressed on 38%.	Tranexamic Acid	47-51	lymphocyte antigen 6 complex, locus A	Mus musculus	8-13
16857898-6	2006	ACE(+)AMCA(+) cells enriched for PCFCs by 170-fold, and colonies were twofold larger than for AMCA(+) selection alone.	Tranexamic Acid	6-10	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	0-3
16488689-10	2006	CONCLUSIONS: For patients undergoing high-risk open heart surgery and receiving tranexamic acid, a phosphorylcholine-coated oxygenator may reduce intraoperative thrombin formation and the associated consumption of platelets, fibrinogen, and antithrombin.	Tranexamic Acid	80-95	coagulation factor II, thrombin	Homo sapiens	161-169
16488689-10	2006	CONCLUSIONS: For patients undergoing high-risk open heart surgery and receiving tranexamic acid, a phosphorylcholine-coated oxygenator may reduce intraoperative thrombin formation and the associated consumption of platelets, fibrinogen, and antithrombin.	Tranexamic Acid	80-95	fibrinogen beta chain	Homo sapiens	225-235
16284553-5	2005	Rapid administration of antifibrinolytic therapy was given by intravenous administration of 2 g tranexamic acid over a period of 10 minutes (RAF).	Tranexamic Acid	96-111	zinc fingers and homeoboxes 2	Homo sapiens	141-144
15952489-2	2005	Since all routine haemostatic parameters were nearly normal, single doses of rFVIIa (90 microg/kg) and of tranexamic acid (15 mg/kg) were administered to improve thrombin generation and reduce fibrinolysis.	Tranexamic Acid	106-121	coagulation factor II, thrombin	Homo sapiens	162-170
16146463-0	2005	The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.	Tranexamic Acid	29-44	coagulation factor II, thrombin	Homo sapiens	48-56
16146463-2	2005	The aim of the study was to examine the effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic activity in patients undergoing cardiac surgery.	Tranexamic Acid	65-80	coagulation factor II, thrombin	Homo sapiens	84-92
16146463-6	2005	Thrombin generation was less in the aprotinin group than in the tranexamic acid and the placebo group (thrombin/anti-thrombin III complexes 33.7 +/- 3.6, 53.6 +/- 7.0 and 44.2 +/- 5.3 microg/l 2 h after CPB and F1 + 2 fragment 1.50 +/- 0.10, 2.37 +/- 0.37 and 2.04 +/- 0.20 nmol/l 6 h after surgery, respectively).	Tranexamic Acid	64-79	coagulation factor II, thrombin	Homo sapiens	0-8
16227196-11	2005	Epsilon aminocaproic acid and tranexamic acid are lysine analogs that reduce bleeding by inhibiting the conversion of plasminogen to plasmin, a serine protease responsible for breaking down fibrinogen to fibrin.	Tranexamic Acid	30-45	plasminogen	Homo sapiens	118-125
16227196-11	2005	Epsilon aminocaproic acid and tranexamic acid are lysine analogs that reduce bleeding by inhibiting the conversion of plasminogen to plasmin, a serine protease responsible for breaking down fibrinogen to fibrin.	Tranexamic Acid	30-45	coagulation factor II, thrombin	Homo sapiens	144-159
15234728-5	2004	Allergological investigations (cutaneous tests, serum IgE concentrations, in vitro histamine-release tests) suggest that this is the first reported case of anaphylactic shock to tranexamic acid.	Tranexamic Acid	178-193	immunoglobulin heavy constant epsilon	Homo sapiens	54-57
14672621-8	2004	The injection of anti-alpha(2)-AP antibody in the WT mice improved the regeneration after the liver injury, and the injection of tranexamic acid in the alpha(2)-AP-/- mice reduced.	Tranexamic Acid	129-144	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	152-163
15194548-1	2004	We clarified the role of fibrinolysis in tissue-factor (TF)-induced rat disseminated intravascular coagulation (DIC) using tranexamic acid (TA).	Tranexamic Acid	123-138	coagulation factor III, tissue factor	Rattus norvegicus	41-54
15194548-1	2004	We clarified the role of fibrinolysis in tissue-factor (TF)-induced rat disseminated intravascular coagulation (DIC) using tranexamic acid (TA).	Tranexamic Acid	123-138	coagulation factor III, tissue factor	Rattus norvegicus	56-58
15194548-1	2004	We clarified the role of fibrinolysis in tissue-factor (TF)-induced rat disseminated intravascular coagulation (DIC) using tranexamic acid (TA).	Tranexamic Acid	140-142	coagulation factor III, tissue factor	Rattus norvegicus	41-54
15194548-1	2004	We clarified the role of fibrinolysis in tissue-factor (TF)-induced rat disseminated intravascular coagulation (DIC) using tranexamic acid (TA).	Tranexamic Acid	140-142	coagulation factor III, tissue factor	Rattus norvegicus	56-58
12154423-9	2002	MEASUREMENTS AND MAIN RESULTS: In the control and tranexamic acid groups, tumor necrosis factor-alpha, IL-6, and IL-10 secretion by whole blood cell cultures were rapidly decreased, whereas IL-8 secretion was unaffected.	Tranexamic Acid	50-65	tumor necrosis factor	Homo sapiens	74-101
12846058-2	2003	OBJECTIVE: In the present study, the effects of plasmin antagonist tranexamic acid (TEA) on urinary pyridinoline excretion rates were investigated in rheumatoid arthritis (RA) patients.	Tranexamic Acid	67-82	plasminogen	Homo sapiens	48-55
12846058-2	2003	OBJECTIVE: In the present study, the effects of plasmin antagonist tranexamic acid (TEA) on urinary pyridinoline excretion rates were investigated in rheumatoid arthritis (RA) patients.	Tranexamic Acid	84-87	plasminogen	Homo sapiens	48-55
12866723-1	2002	Effects of theophylline, lidocaine, cyclophosphamide, hyoscine N-butyl bromide, tranexamic acid and cytarabine on hexokinase (HK) from human erythrocytes have been investigated in vitro.	Tranexamic Acid	80-95	hexokinase 1	Homo sapiens	126-128
14572819-3	2003	The antifibrinolytic agents aprotinin, tranexamic acid, and epsilon-aminocaproic acid are useful for prophylaxis and treatment of angioedema, likely by inhibiting plasmin.	Tranexamic Acid	39-54	plasminogen	Homo sapiens	163-170
12154423-9	2002	MEASUREMENTS AND MAIN RESULTS: In the control and tranexamic acid groups, tumor necrosis factor-alpha, IL-6, and IL-10 secretion by whole blood cell cultures were rapidly decreased, whereas IL-8 secretion was unaffected.	Tranexamic Acid	50-65	interleukin 6	Homo sapiens	103-107
12154423-9	2002	MEASUREMENTS AND MAIN RESULTS: In the control and tranexamic acid groups, tumor necrosis factor-alpha, IL-6, and IL-10 secretion by whole blood cell cultures were rapidly decreased, whereas IL-8 secretion was unaffected.	Tranexamic Acid	50-65	interleukin 10	Homo sapiens	113-118
12154423-9	2002	MEASUREMENTS AND MAIN RESULTS: In the control and tranexamic acid groups, tumor necrosis factor-alpha, IL-6, and IL-10 secretion by whole blood cell cultures were rapidly decreased, whereas IL-8 secretion was unaffected.	Tranexamic Acid	50-65	C-X-C motif chemokine ligand 8	Homo sapiens	190-194
11927131-6	2002	Increasing concentrations of tranexamic acid resulted in a continuous increase of K(i initial) until a plateau was reached which was similar for all plasmin types.	Tranexamic Acid	29-44	plasminogen	Homo sapiens	149-156
10570059-8	1999	Increased survival of topo IIbeta -/- cells compared with topo IIbeta +/+ cells was observed after treatment with amsacrine (mAMSA), methyl N-(4"-[9-acridinylamino]-2-methoxyphenyl) carbamate hydrochloride (AMCA), methyl N-(4"-[9-acridinylamino]-2-methoxyphenyl)carbamate hydrochloride (mAMCA), mitoxantrone, and etoposide.	Tranexamic Acid	207-211	ATPase, class II, type 9B	Mus musculus	27-33
11431944-7	2001	A significant (p = 0.010) decrease in alpha 2-plasmin inhibitor was noted at 5 and 60 minutes after the start of cardiopulmonary bypass in the tranexamic acid group.	Tranexamic Acid	143-158	serpin family F member 2	Homo sapiens	38-63
11431944-9	2001	alpha 2-plasmin inhibitor-plasmin complexes in the tranexamic acid group were significantly (p = 0.030) lower than in controls 60 minutes after the start of cardiopulmonary bypass, just prior to the end of cardiopulmonary bypass, and after protamine administration.	Tranexamic Acid	51-66	serpin family F member 2	Homo sapiens	0-25
11738071-8	2001	In the tranexamic acid group, fibrinolytic activity and secondary fibrinolysis as measured by t-PA activity and D-dimer were markedly suppressed during CPB surgery (P=.042 and P=.015, respectively).	Tranexamic Acid	7-22	plasminogen activator, tissue type	Homo sapiens	94-98
11738071-12	2001	In a randomized, prospective trial of patients undergoing CPB surgery, we demonstrated that the synthetic antifibrinolytic drug tranexamic acid effectively suppresses fibrinolysis by inhibiting t-PA and plasmin activity with clear reduction of perioperative blood loss.	Tranexamic Acid	128-143	plasminogen activator, tissue type	Homo sapiens	194-198
11389038-4	2001	Plasmin-mediated mRNA expression was inhibited in a concentration-dependent manner by the lysine analogue trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA).	Tranexamic Acid	106-156	plasminogen	Homo sapiens	0-7
11389038-4	2001	Plasmin-mediated mRNA expression was inhibited in a concentration-dependent manner by the lysine analogue trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA).	Tranexamic Acid	158-164	plasminogen	Homo sapiens	0-7
10921506-3	2000	Here, we examined (1) the effects of TXA or APR on basal vascular permeability (VP) and (2) the effects of TXA or APR on platelet-activating factor (PAF)-induced increase of VP in normal unanesthetized rats.	Tranexamic Acid	37-40	PCNA clamp associated factor	Rattus norvegicus	149-152
10921506-3	2000	Here, we examined (1) the effects of TXA or APR on basal vascular permeability (VP) and (2) the effects of TXA or APR on platelet-activating factor (PAF)-induced increase of VP in normal unanesthetized rats.	Tranexamic Acid	107-110	PCNA clamp associated factor	Rattus norvegicus	121-147
10921506-3	2000	Here, we examined (1) the effects of TXA or APR on basal vascular permeability (VP) and (2) the effects of TXA or APR on platelet-activating factor (PAF)-induced increase of VP in normal unanesthetized rats.	Tranexamic Acid	107-110	PCNA clamp associated factor	Rattus norvegicus	149-152
10921506-10	2000	Pre-treatment with TXA decreased PAF-induced increases of VP in the microcirculation of the thoracic and abdominal aorta, the duodenum and the pancreas, from 35% to 41%.	Tranexamic Acid	19-22	PCNA clamp associated factor	Rattus norvegicus	33-36
10959704-6	2000	Tranexamic acid (0.8 mM) is incorporated in the reaction mixture resulting in a 19-fold increase in the rate of plasminogen activation and presumably an about 50-fold decrease in the rate of inhibition of generated plasmin by plasmin inhibitor.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	112-119
10959704-6	2000	Tranexamic acid (0.8 mM) is incorporated in the reaction mixture resulting in a 19-fold increase in the rate of plasminogen activation and presumably an about 50-fold decrease in the rate of inhibition of generated plasmin by plasmin inhibitor.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	215-222
10930090-5	2000	In contrast, the effect of BCC-derived medium on collagen amount was attenuated by inhibitors of matrix metalloproteinases (MMPs) as well as by tranexamic acid, an inhibitor of the plasminogen conversion to plasmin, while it was abolished in presence of the two kinds of proteinase inhibitors.	Tranexamic Acid	144-159	plasminogen	Homo sapiens	181-188
10570059-9	1999	These studies showed that topo IIbeta -/- cells were significantly more resistant to mAMSA, AMCA, mAMCA, and mitoxantrone, than topo IIbeta +/+ cells, indicating that topo IIbeta is an important target for the cytotoxic effects of these compounds.	Tranexamic Acid	92-96	ATPase, class II, type 9B	Mus musculus	31-37
10188764-6	1999	Results are less consistent with tranexamic acid: high dose aprotinin either reduces blood loss significantly more than, or to an equivalent level to, tranexamic acid.	Tranexamic Acid	33-48	pancreatic trypsin inhibitor	Bos taurus	60-69
10517115-6	1999	Only tranexamic acid (inhibiting fibrinolysis) could at last stop the symptomatic episodes of gastrointestinal bleeding despite the fact of decreasing von Willebrand factor.	Tranexamic Acid	5-20	von Willebrand factor	Homo sapiens	151-172
10221476-8	1999	The increased fibrinolytic activity and the rise in soluble thrombomodulin were suppressed by the preadministration of tranexamic acid, resulting in remarkably improved pulmonary function during reperfusion.	Tranexamic Acid	119-134	thrombomodulin	Oryctolagus cuniculus	60-74
10625440-1	1999	The kringle 2 (K2) module of human plasminogen (Pgn) binds L-lysine and analogous zwitterionic compounds, such as the antifibronolytic agent trans-(aminomethyl)cyclohexanecarboxylic acid (AMCHA).	Tranexamic Acid	188-193	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	48-51
10625440-13	1999	In most K2 structures, the N atom of AMCHA places itself approximately 3.9 and 4.4A from the anionic groups of Glu(57) and Asp(55), respectively, while its carboxylate group, H-bonded to the Tyr(36) side chain OH(eta), ion-pairs the Arg(71) guanidinium group.	Tranexamic Acid	37-42	endothelin receptor type A	Homo sapiens	213-216
10544908-3	1999	Our aim was to explore the effect of inhibiting both plasmin action with tranexamic acid (TA) and thrombin production with low molecular weight heparin (LMWH), on the bleeding time (BT) and platelet function in patients with CRF.	Tranexamic Acid	73-88	plasminogen	Homo sapiens	53-60
10544908-3	1999	Our aim was to explore the effect of inhibiting both plasmin action with tranexamic acid (TA) and thrombin production with low molecular weight heparin (LMWH), on the bleeding time (BT) and platelet function in patients with CRF.	Tranexamic Acid	90-92	plasminogen	Homo sapiens	53-60
9192782-6	1997	The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites.	Tranexamic Acid	76-126	plasminogen	Homo sapiens	4-11
9816408-8	1998	Epsilon-aminocaproic acid and tranexamic acid inhibit the formation of plasmin and fragments of the Hageman factor, thus inhibiting kallikrein and bradykinin production.	Tranexamic Acid	30-45	coagulation factor XII	Homo sapiens	100-114
9816408-8	1998	Epsilon-aminocaproic acid and tranexamic acid inhibit the formation of plasmin and fragments of the Hageman factor, thus inhibiting kallikrein and bradykinin production.	Tranexamic Acid	30-45	kallikrein related peptidase 4	Homo sapiens	132-142
9816408-8	1998	Epsilon-aminocaproic acid and tranexamic acid inhibit the formation of plasmin and fragments of the Hageman factor, thus inhibiting kallikrein and bradykinin production.	Tranexamic Acid	30-45	kininogen 1	Homo sapiens	147-157
9192782-6	1997	The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites.	Tranexamic Acid	76-126	plasminogen	Homo sapiens	163-170
9192782-6	1997	The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites.	Tranexamic Acid	128-134	plasminogen	Homo sapiens	4-11
9192782-6	1997	The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites.	Tranexamic Acid	128-134	plasminogen	Homo sapiens	163-170
9275473-4	1996	The inhibitors of u-PA and plasmin, tranexamic acid and 6-aminocaproic acid, obviously inhibited the u-PA activity and the invasive potential of QBC939 cells.	Tranexamic Acid	36-51	plasminogen activator, urokinase	Homo sapiens	101-105
9003434-5	1997	Lysine-dependent plasminogen binding to r-alpha-enolase was demonstrated by a greater than 80% inhibition of binding by the lysine analogues epsilon-amino caproic acid and tranexamic acid, whilst only 14% inhibition occurred with the arginine analogue benzamidine.	Tranexamic Acid	172-187	enolase 1	Homo sapiens	42-55
9117184-8	1997	This effect could be inhibited by anti-u-PA antibodies, as well as by tranexamic acid and by aprotinin, indicating that the degrading activity is u-PA mediated and plasmin dependent.	Tranexamic Acid	70-85	plasminogen activator, urokinase	Homo sapiens	146-150
9174292-3	1997	The protease inhibitors aprotinin and tranexamic acid, which are used to reduce blood loss after cardiac surgery, were evaluated in vitro on cytokine-induced iNOS expression and the resulting NO production to demonstrate the relative antiinflammatory effects of each drug.	Tranexamic Acid	38-53	nitric oxide synthase 2, inducible	Mus musculus	158-162
9102163-13	1997	The relevance of the modifications of the fibrinolytic balance of mouse microvascular endothelium in bFGF-induced angiogenesis was validated in vivo by a gelatin-sponge assay in which the plasmin inhibitors tranexamic acid and epsilon-aminocaproic acid given to mice in the drinking water inhibited neovascularization induced by the growth factor.	Tranexamic Acid	207-222	fibroblast growth factor 2	Mus musculus	101-105
9135499-5	1997	AMCA-induced topoisomerase cleavage sites on pBR322, C-MYC and SV40 DNA were investigated using agarose or sequencing gels.	Tranexamic Acid	0-4	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	53-58
7925643-9	1994	Detachment was prevented by an anticatalytic anti-uPA antibody, by the plasmin-specific inhibitor aprotinin, and by the lysine analogue tranexamic acid, the latter of which prevents plasmin(ogen) binding to the cell surface.	Tranexamic Acid	136-151	plasminogen	Homo sapiens	182-189
8654567-4	1996	Substantial reductions in k1 were seen in the presence of trans-4-(aminomethyl)cyclohexane-1-carboxylic acid at concentrations corresponding to lysine-binding site interactions at kringle 4 of plasmin; at saturation the rate constant is reduced 20-fold, whereas the effect of saturation of kringle 1 is only a 2-fold reduction.	Tranexamic Acid	58-108	plasminogen	Homo sapiens	193-200
8646816-3	1996	The effects of lysine derivatives such as epsilon-aminocaproic acid (EACA) and tranexamic acid on bovine plasmin activity were investigated.	Tranexamic Acid	79-94	plasminogen	Bos taurus	105-112
8646816-5	1996	However, the bovine plasmin activity became stable upon adding EACA or tranexamic acid.	Tranexamic Acid	71-86	plasminogen	Bos taurus	20-27
8646816-7	1996	On the other hand, when plasmin was incubated at 37 degrees C for 1, 3 or 5 days with tranexamic acid, its activity remained at 110%, 95.6% and 85.9%, respectively.	Tranexamic Acid	86-101	plasminogen	Bos taurus	24-31
8646816-9	1996	However, when bovine plasmin had been incubated for 5 days at 37 degrees C in the presence of tranexamic acid, the residual plasmin activity was more than 80%.	Tranexamic Acid	94-109	plasminogen	Bos taurus	21-28
8646816-9	1996	However, when bovine plasmin had been incubated for 5 days at 37 degrees C in the presence of tranexamic acid, the residual plasmin activity was more than 80%.	Tranexamic Acid	94-109	plasminogen	Bos taurus	124-131
7586221-8	1995	Tranexamic acid, a plasmin inhibitor, abrogated the stimulation of SMC migration by IL-4.	Tranexamic Acid	0-15	interleukin 4	Homo sapiens	84-88
7994858-11	1994	However, emboli recovered from animals receiving PAI-1 still harbored immunoreactive PAI-1 and were, on average, more than twofold greater in mass (393 +/- 56 mg) than emboli recovered from either controls (183 +/- 76 mg) or animals receiving TXA (180 +/- 80 mg).	Tranexamic Acid	243-246	serpin family E member 1	Canis lupus familiaris	49-54
7531000-0	1994	Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.	Tranexamic Acid	53-68	plasminogen	Homo sapiens	72-79
8579642-1	1994	We reviewed the records of 66 patients who underwent cardiopulmonary bypass; half of these patients received the plasmin inhibitor, tranexamic acid.	Tranexamic Acid	132-147	plasminogen	Homo sapiens	113-120
7531000-7	1994	These results support the idea that aprotinin inhibition of plasmin is a primary mode of action in vivo, and suggest that combination therapy of aprotinin with tranexamic acid might be more effective than either inhibitor alone.	Tranexamic Acid	160-175	plasminogen	Homo sapiens	60-67
8073394-1	1994	The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (t-PA).	Tranexamic Acid	58-106	plasminogen activator, tissue type	Homo sapiens	257-291
8073394-1	1994	The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (t-PA).	Tranexamic Acid	108-112	plasminogen activator, tissue type	Homo sapiens	257-291
8073394-4	1994	AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	Tranexamic Acid	0-4	plasminogen activator, tissue type	Homo sapiens	162-166
8073394-4	1994	AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	Tranexamic Acid	0-4	plasminogen activator, tissue type	Homo sapiens	236-240
8428801-4	1993	Plasmin generation was abolished and pro-u-PA accumulated in cell cultures that were grown for several days, either in the presence of serum thoroughly depleted of plasminogen, or in the presence of 1 mM tranexamic acid.	Tranexamic Acid	204-219	plasminogen	Homo sapiens	0-7
8501135-7	1993	Quantitative comparison of the cell surface localized tPA, which was eluted by tranexamic acid, with the total cellular tPA showed that cell surface bound tPA could represent up to 10%.	Tranexamic Acid	79-94	plasminogen activator, tissue type	Homo sapiens	54-57
7679575-6	1993	Tranexamic acid inhibited the digestion of thrombospondin by plasmin and miniplasmin, suggesting an important role for the kringle-5 domain in this process.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	61-68
8501135-3	1993	Elution of tPA from the cell layers indicated that polylysine (5 micrograms/ml) and tranexamic acid (10 mM), an analog of lysine, were the most efficient agents for disrupting the interaction between tPA and cell surface component(s).	Tranexamic Acid	84-99	plasminogen activator, tissue type	Homo sapiens	11-14
8501135-3	1993	Elution of tPA from the cell layers indicated that polylysine (5 micrograms/ml) and tranexamic acid (10 mM), an analog of lysine, were the most efficient agents for disrupting the interaction between tPA and cell surface component(s).	Tranexamic Acid	84-99	plasminogen activator, tissue type	Homo sapiens	200-203
8383426-5	1993	Induction of the early phase of plasmin"s effect required both the lysine binding and catalytic sites in plasmin molecule because it was inhibited either by the binding antagonist tranexamic acid or by the serine protease inhibitor aprotinin.	Tranexamic Acid	180-195	plasminogen	Homo sapiens	32-39
8383426-5	1993	Induction of the early phase of plasmin"s effect required both the lysine binding and catalytic sites in plasmin molecule because it was inhibited either by the binding antagonist tranexamic acid or by the serine protease inhibitor aprotinin.	Tranexamic Acid	180-195	plasminogen	Homo sapiens	105-112
8383426-7	1993	The late phase of plasmin"s effect was due to the catalytic activity because it was inhibited by aprotinin but not by tranexamic acid.	Tranexamic Acid	118-133	plasminogen	Homo sapiens	18-25
8428801-7	1993	Most of the bound plasmin could be washed off cells with 10 mM tranexamic acid, but complete removal of plasmin from the cell surface required washing of the cells with acid-glycine pH 3.0.	Tranexamic Acid	63-78	plasminogen	Homo sapiens	18-25
1703440-6	1991	In the presence of tranexamic acid or 6-aminohexanoic acid, lysine analogues that mimic the effects of fibrin, plasmin binding kinetics are changed such that equilibrium is reached slowly following a lag phase after mixing of enzyme and inhibitor.	Tranexamic Acid	19-34	plasminogen	Homo sapiens	111-118
1795552-3	1991	In the study we show confocal laser microscopical imaging of fluorescent motoneurons labelled by retrograde transport of fluoro-gold and AMCA-fluorescent axon terminals labelled with antisera against immunogenes as thyrotropin-releasing hormone (TRH) and calcitonin gene-related peptide (CGRP).	Tranexamic Acid	137-141	thyrotropin releasing hormone	Homo sapiens	215-244
1795552-3	1991	In the study we show confocal laser microscopical imaging of fluorescent motoneurons labelled by retrograde transport of fluoro-gold and AMCA-fluorescent axon terminals labelled with antisera against immunogenes as thyrotropin-releasing hormone (TRH) and calcitonin gene-related peptide (CGRP).	Tranexamic Acid	137-141	thyrotropin releasing hormone	Homo sapiens	246-249
1795552-3	1991	In the study we show confocal laser microscopical imaging of fluorescent motoneurons labelled by retrograde transport of fluoro-gold and AMCA-fluorescent axon terminals labelled with antisera against immunogenes as thyrotropin-releasing hormone (TRH) and calcitonin gene-related peptide (CGRP).	Tranexamic Acid	137-141	calcitonin related polypeptide alpha	Homo sapiens	255-286
1795552-3	1991	In the study we show confocal laser microscopical imaging of fluorescent motoneurons labelled by retrograde transport of fluoro-gold and AMCA-fluorescent axon terminals labelled with antisera against immunogenes as thyrotropin-releasing hormone (TRH) and calcitonin gene-related peptide (CGRP).	Tranexamic Acid	137-141	calcitonin related polypeptide alpha	Homo sapiens	288-292
1716481-1	1991	In the present study, we systematically investigated aprotinin, epsilon-aminocaproic acid (EACA) and tranexamic acid as inhibitors of fibrinogen breakdown and of the generation of fibrinogen degradation products (FgDP).	Tranexamic Acid	101-116	fibrinogen beta chain	Homo sapiens	134-144
1848244-6	1991	Both epsilon-aminocaproic acid and tranexamic acid prevented actin"s inhibition of plasmin, suggesting that accessible lysine residues of actin interact with the kringle (lysine-binding) regions of plasmin.	Tranexamic Acid	35-50	actin	Oryctolagus cuniculus	61-66
1848244-6	1991	Both epsilon-aminocaproic acid and tranexamic acid prevented actin"s inhibition of plasmin, suggesting that accessible lysine residues of actin interact with the kringle (lysine-binding) regions of plasmin.	Tranexamic Acid	35-50	actin	Oryctolagus cuniculus	138-143
1533399-7	1992	Pretreatment of PMN with either active-site-inhibited plasmin or tranexamic acid prevented PMN aggregation by plasmin, indicating that both binding of plasmin to the cell surface via the lysine binding sites and catalysis were required for the response.	Tranexamic Acid	65-80	plasminogen	Homo sapiens	110-117
1533399-7	1992	Pretreatment of PMN with either active-site-inhibited plasmin or tranexamic acid prevented PMN aggregation by plasmin, indicating that both binding of plasmin to the cell surface via the lysine binding sites and catalysis were required for the response.	Tranexamic Acid	65-80	plasminogen	Homo sapiens	110-117
1951300-4	1991	Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL).	Tranexamic Acid	28-43	plasminogen	Homo sapiens	58-65
1951300-4	1991	Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL).	Tranexamic Acid	200-215	plasminogen	Homo sapiens	58-65
1951300-4	1991	Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL).	Tranexamic Acid	200-215	plasminogen	Homo sapiens	150-157
1951300-4	1991	Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL).	Tranexamic Acid	200-215	plasminogen	Homo sapiens	150-157
1951300-5	1991	Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets.	Tranexamic Acid	25-40	plasminogen	Homo sapiens	0-7
1951300-5	1991	Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets.	Tranexamic Acid	25-40	coagulation factor II, thrombin	Homo sapiens	73-81
1951300-5	1991	Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets.	Tranexamic Acid	25-40	plasminogen	Homo sapiens	157-164
1951300-5	1991	Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets.	Tranexamic Acid	132-147	plasminogen	Homo sapiens	0-7
1951300-5	1991	Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets.	Tranexamic Acid	132-147	coagulation factor II, thrombin	Homo sapiens	73-81
1951300-5	1991	Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets.	Tranexamic Acid	132-147	plasminogen	Homo sapiens	157-164
1951300-7	1991	Tranexamic acid blocks plasmin-induced partial platelet activation during ECC, thus preserving platelet function and promoting hemostasis after ECC.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	23-30
1806461-0	1991	Intramedullary multiple hematomas in siblings with congenital alpha-2-plasmin inhibitor deficiency: orthopedic surgery with protection by tranexamic acid.	Tranexamic Acid	138-153	serpin family F member 2	Homo sapiens	62-87
1960888-6	1991	Consequently, it was thought that AMCaADP was stiffer than AM and the crossbridges with either bound Ca (AMCa) or ADP (AM.ADP), the latter three kinds of the crossbridges being formed directly from AM, not as a result of ATP hydrolysis.	Tranexamic Acid	34-38	WD and tetratricopeptide repeats 1	Homo sapiens	119-125
1693450-6	1990	Major finding of plasma parameters of fibrinolysis is that alpha 2AP which had been unable to inhibit plasmin, became able to inhibit it after the administration of tranexamic acid.	Tranexamic Acid	165-180	serpin family F member 2	Homo sapiens	59-68
1712633-4	1990	After incubation of the melanoma cells with 10% plasminogen-depleted fetal calf serum and human plasminogen, bound plasmin activity could be eluted from the cell surface with tranexamic acid, an analogue of lysine.	Tranexamic Acid	175-190	plasminogen	Homo sapiens	48-55
33764862-0	2021	[Tranexamic Acid Reduces the Incidence of Heterotopic Ossifications after Elective Primary Total Hip Arthroplasty].	Tranexamic Acid	1-16	hedgehog interacting protein	Homo sapiens	97-100
33764862-12	2021	RESULTS Tranexamic acid protocol significantly reduces the incidence of heterotopic ossification after elective primary total hip replacement.	Tranexamic Acid	8-23	hedgehog interacting protein	Homo sapiens	126-129
34920046-10	2022	Patients in the TXA group had fewer re-operations for bleeding or tamponade (Odd ratio (OR) = 0.82, p = 0.044), less blood loss after surgery (p < 0.001), and a lower risk for blood transfusion exposure (OR = 0.45, p < 0.001) than those in the no-TXA group.	Tranexamic Acid	16-19	odd-skipped related transcription factor 1	Homo sapiens	77-80
34410441-7	2022	Good linearity was achieved (R2 > 0.998) for TXA concentrations in urine ranging from 300 to 3000 ng mL-1, with LOD and LOQ of 30 and 65 ng mL-1, respectively.	Tranexamic Acid	45-48	L1 cell adhesion molecule	Mus musculus	101-105
34644431-4	2021	We aimed to study, in FVIII knockout mice (FVIII-KO), whether haemostasis is improved with the addition of tranexamic acid (TxAc) to emicizumab.	Tranexamic Acid	124-128	coagulation factor VIII	Mus musculus	22-27
34930351-9	2021	In contrast to ALM-treated animals, systemic inflammatory markers remained elevated at day 5 (IL-6, IL-12, IL-10, platelet count) and day 28 (IL-1beta, IL-10) following surgery in TXA-treated animals.	Tranexamic Acid	180-183	interleukin 6	Rattus norvegicus	94-98
34930351-9	2021	In contrast to ALM-treated animals, systemic inflammatory markers remained elevated at day 5 (IL-6, IL-12, IL-10, platelet count) and day 28 (IL-1beta, IL-10) following surgery in TXA-treated animals.	Tranexamic Acid	180-183	interleukin 12B	Rattus norvegicus	100-105
34930351-9	2021	In contrast to ALM-treated animals, systemic inflammatory markers remained elevated at day 5 (IL-6, IL-12, IL-10, platelet count) and day 28 (IL-1beta, IL-10) following surgery in TXA-treated animals.	Tranexamic Acid	180-183	interleukin 10	Rattus norvegicus	107-112
34930351-9	2021	In contrast to ALM-treated animals, systemic inflammatory markers remained elevated at day 5 (IL-6, IL-12, IL-10, platelet count) and day 28 (IL-1beta, IL-10) following surgery in TXA-treated animals.	Tranexamic Acid	180-183	interleukin 1 alpha	Rattus norvegicus	142-150
34930351-9	2021	In contrast to ALM-treated animals, systemic inflammatory markers remained elevated at day 5 (IL-6, IL-12, IL-10, platelet count) and day 28 (IL-1beta, IL-10) following surgery in TXA-treated animals.	Tranexamic Acid	180-183	interleukin 10	Rattus norvegicus	152-157
34862827-0	2022	Tranexamic acid inhibits melanogenesis partially via stimulation of TGF-beta1 expression in human epidermal keratinocytes.	Tranexamic Acid	0-15	transforming growth factor beta 1	Homo sapiens	68-77
34862827-2	2022	OBJECTIVE: The present study aimed to demonstrate the effect of TA on melanogenesis via regulation of TGF-beta1 expression in keratinocytes.	Tranexamic Acid	64-66	transforming growth factor beta 1	Homo sapiens	102-111
34862827-4	2022	Then the mRNA and protein levels of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1) of human epidermal melanocytes (NHEMs) in presence of TA-treated KCM were evaluated via RT-PCR and Western blot analysis.	Tranexamic Acid	204-206	melanocyte inducing transcription factor	Homo sapiens	36-82
34862827-4	2022	Then the mRNA and protein levels of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1) of human epidermal melanocytes (NHEMs) in presence of TA-treated KCM were evaluated via RT-PCR and Western blot analysis.	Tranexamic Acid	204-206	melanocyte inducing transcription factor	Homo sapiens	84-88
34862827-4	2022	Then the mRNA and protein levels of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1) of human epidermal melanocytes (NHEMs) in presence of TA-treated KCM were evaluated via RT-PCR and Western blot analysis.	Tranexamic Acid	204-206	tyrosinase	Homo sapiens	91-101
34862827-4	2022	Then the mRNA and protein levels of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1) of human epidermal melanocytes (NHEMs) in presence of TA-treated KCM were evaluated via RT-PCR and Western blot analysis.	Tranexamic Acid	204-206	tyrosinase	Homo sapiens	103-106
34862827-4	2022	Then the mRNA and protein levels of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1) of human epidermal melanocytes (NHEMs) in presence of TA-treated KCM were evaluated via RT-PCR and Western blot analysis.	Tranexamic Acid	204-206	tyrosinase related protein 1	Homo sapiens	113-141
34862827-4	2022	Then the mRNA and protein levels of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-1 (TRP-1) of human epidermal melanocytes (NHEMs) in presence of TA-treated KCM were evaluated via RT-PCR and Western blot analysis.	Tranexamic Acid	204-206	tyrosinase related protein 1	Homo sapiens	143-148
34862827-7	2022	RESULTS: The mRNA and protein levels of TGF-beta1 in keratinocytes were significantly increased after TA treatment.	Tranexamic Acid	102-104	transforming growth factor beta 1	Homo sapiens	40-49
34862827-8	2022	Melanin contents, tyrosinase activity, protein and mRNA levels of TYR, MITF, and TRP-1 were downregulated in NHEMs in the presence of TA-treated KCM.	Tranexamic Acid	134-136	tyrosinase	Homo sapiens	18-28
34862827-8	2022	Melanin contents, tyrosinase activity, protein and mRNA levels of TYR, MITF, and TRP-1 were downregulated in NHEMs in the presence of TA-treated KCM.	Tranexamic Acid	134-136	tyrosinase	Homo sapiens	66-69
34862827-8	2022	Melanin contents, tyrosinase activity, protein and mRNA levels of TYR, MITF, and TRP-1 were downregulated in NHEMs in the presence of TA-treated KCM.	Tranexamic Acid	134-136	melanocyte inducing transcription factor	Homo sapiens	71-75
34862827-8	2022	Melanin contents, tyrosinase activity, protein and mRNA levels of TYR, MITF, and TRP-1 were downregulated in NHEMs in the presence of TA-treated KCM.	Tranexamic Acid	134-136	tyrosinase related protein 1	Homo sapiens	81-86
34862827-9	2022	Knockdown of TGF-beta1 in keratinocytes could attenuate the inhibitory effect of TA-treated KCM on melanogenesis.	Tranexamic Acid	81-83	transforming growth factor beta 1	Homo sapiens	13-22
34596008-4	2021	In vitro cell studies using human A375 melanoma cells show that HA/TA-LP can promote the uptake of TA by targeting delivery with resulting inhibition of tyrosinase activity and melanin production.	Tranexamic Acid	99-101	tyrosinase	Homo sapiens	153-163
34703327-1	2021	Tranexamic acid (TXA) is a lysine analog that exhibits an anti-fibrinolytic effect by directly preventing the activation of plasminogen as well as inhibiting activated plasmin from degrading fibrin clots, thereby promoting hemostasis and reducing the duration and quantity of blood loss.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	168-175
34409492-7	2021	RESULTS: Compared with single-dose TXA, patients received three dose TXA had significantly reduced WBC counts and fibrinogen/fibrin degradation product (FDP) levels, increased albumin and fibrinogen levels, and prolonged PT on post-operative day (POD) three.	Tranexamic Acid	69-72	fibrinogen beta chain	Homo sapiens	114-124
34409492-7	2021	RESULTS: Compared with single-dose TXA, patients received three dose TXA had significantly reduced WBC counts and fibrinogen/fibrin degradation product (FDP) levels, increased albumin and fibrinogen levels, and prolonged PT on post-operative day (POD) three.	Tranexamic Acid	69-72	albumin	Homo sapiens	176-183
34409492-7	2021	RESULTS: Compared with single-dose TXA, patients received three dose TXA had significantly reduced WBC counts and fibrinogen/fibrin degradation product (FDP) levels, increased albumin and fibrinogen levels, and prolonged PT on post-operative day (POD) three.	Tranexamic Acid	69-72	fibrinogen beta chain	Homo sapiens	188-198
34409492-8	2021	Though patients received three dose TXA had a tendency that increased Hb, decreased CK, reduced D-D, and prolonged APTT on POD3, it is not statistically significant.	Tranexamic Acid	36-39	cytidine/uridine monophosphate kinase 1	Homo sapiens	84-86
34409492-11	2021	CONCLUSION: Three-dose TXA contribute to attenuate early post-operative systemic inflammatory response and nutritional loss, increase fibrinogen, reduce FDP levels, and prolong PT in THA patients within an ERAS pathway, which may associate with reduced early post-operative haemorrhagic tendency, thrombosis risks, and hypercoagulability.	Tranexamic Acid	23-26	fibrinogen beta chain	Homo sapiens	134-144
34409492-11	2021	CONCLUSION: Three-dose TXA contribute to attenuate early post-operative systemic inflammatory response and nutritional loss, increase fibrinogen, reduce FDP levels, and prolong PT in THA patients within an ERAS pathway, which may associate with reduced early post-operative haemorrhagic tendency, thrombosis risks, and hypercoagulability.	Tranexamic Acid	23-26	ES cell expressed Ras	Homo sapiens	206-210
34703327-1	2021	Tranexamic acid (TXA) is a lysine analog that exhibits an anti-fibrinolytic effect by directly preventing the activation of plasminogen as well as inhibiting activated plasmin from degrading fibrin clots, thereby promoting hemostasis and reducing the duration and quantity of blood loss.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	168-175
34627673-10	2022	MMP-9 was elevated in the placebo group early postoperatively and in the TXA group at the immediate postoperative time point and after 24 hours.	Tranexamic Acid	73-76	matrix metallopeptidase 9	Homo sapiens	0-5
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	108-123	anti-Mullerian hormone	Homo sapiens	231-234
34692327-3	2021	Tranexamic acid (TXA) is used as an alternative for the treatment of hereditary angioedema and it may be an attractive option for the treatment of ACE inhibitor-induced angioedema (ACEi-AE) in the emergency department (ED).	Tranexamic Acid	0-15	angiotensin I converting enzyme	Homo sapiens	147-150
34692327-3	2021	Tranexamic acid (TXA) is used as an alternative for the treatment of hereditary angioedema and it may be an attractive option for the treatment of ACE inhibitor-induced angioedema (ACEi-AE) in the emergency department (ED).	Tranexamic Acid	17-20	angiotensin I converting enzyme	Homo sapiens	147-150
34534255-6	2021	Furthermore, tranexamic acid exerted inhibitory effects on TMPRSS2 protease activity.	Tranexamic Acid	13-28	transmembrane serine protease 2	Homo sapiens	59-66
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	108-123	anti-Mullerian hormone	Homo sapiens	207-229
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	293-308	anti-Mullerian hormone	Homo sapiens	207-229
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	293-308	anti-Mullerian hormone	Homo sapiens	231-234
34481524-6	2021	The primary outcome was the feasibility of conducting a definitive trial in terms of design and procedures (such as recruitment rate, retention, safety of intravenous 1 gm of TXA, sample size verification) and assess the efficacy of TXA on the ovarian reserve and intra-operative blood loss by comparing mean difference of AMH levels between TXA and control groups at pre- and 3 months post-surgery.	Tranexamic Acid	342-345	anti-Mullerian hormone	Homo sapiens	323-326
34481524-9	2021	The mean difference of serum AMH levels (pre- and 3 months post-surgery) between the TXA and control groups was not significantly different.	Tranexamic Acid	85-88	anti-Mullerian hormone	Homo sapiens	29-32
34225366-12	2021	This is most likely explained by the synergistic antifibrotic effect of TXA with adipokines, such as plasminogen activator inhibitor-1 (PAI-1), found in the femoral bone marrow which is perforated using CI.	Tranexamic Acid	72-75	serpin family E member 1	Homo sapiens	101-134
34229096-0	2021	Perioperative Tranexamic Acid for ACTH-secreting Pituitary Adenomas: Implementation Protocol Results & Trial Prospectus.	Tranexamic Acid	14-29	proopiomelanocortin	Homo sapiens	34-38
34305348-0	2021	A break-even analysis of tranexamic acid for prevention of periprosthetic joint infection following total hip and knee arthroplasty.	Tranexamic Acid	25-40	hedgehog interacting protein	Homo sapiens	106-109
34401422-2	2021	As different routes of local TXA administration have been proposed to minimize systemic complications, we aimed to investigate the effectiveness and systemic absorption of peri-articular (PA) and intra-articular (IA) administration of TXA after primary TKA.	Tranexamic Acid	29-32	perilipin 1	Homo sapiens	172-176
34342666-0	2021	Tranexamic acid is safe and effective in patients with heterozygous factor V Leiden mutation during total joint arthroplasty.	Tranexamic Acid	0-15	coagulation factor V	Homo sapiens	68-83
34342666-3	2021	There is no study that specifically analyzes the safety and efficacy of TXA during TJA in patients with factor V Leiden (FVL) mutation; therefore, the purpose of this study was to evaluate the safety and efficacy of TXA use on the risk of VTE and bleeding in patients carrying FVL mutation.	Tranexamic Acid	216-219	coagulation factor V	Homo sapiens	104-119
34342666-3	2021	There is no study that specifically analyzes the safety and efficacy of TXA during TJA in patients with factor V Leiden (FVL) mutation; therefore, the purpose of this study was to evaluate the safety and efficacy of TXA use on the risk of VTE and bleeding in patients carrying FVL mutation.	Tranexamic Acid	216-219	coagulation factor V	Homo sapiens	121-124
34342666-3	2021	There is no study that specifically analyzes the safety and efficacy of TXA during TJA in patients with factor V Leiden (FVL) mutation; therefore, the purpose of this study was to evaluate the safety and efficacy of TXA use on the risk of VTE and bleeding in patients carrying FVL mutation.	Tranexamic Acid	216-219	coagulation factor V	Homo sapiens	277-280
34342666-12	2021	CONCLUSIONS: The combined local and systemic administration of TXA could be safely used in patients with heterozygous FVL mutation receiving pharmacological thromboprophylaxis during TJA without increasing the risk of VTE.	Tranexamic Acid	63-66	coagulation factor V	Homo sapiens	118-121
34225366-12	2021	This is most likely explained by the synergistic antifibrotic effect of TXA with adipokines, such as plasminogen activator inhibitor-1 (PAI-1), found in the femoral bone marrow which is perforated using CI.	Tranexamic Acid	72-75	serpin family E member 1	Homo sapiens	136-141
34065949-6	2021	Tranexamic acid is an antifibrinolytic agent which inhibits the conversion of plasminogen to plasmin.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	93-100
34458114-15	2021	As the number of cases of hip fractures continues to increase along with increase in age, so the use of TXA in such cases may improve clinical outcomes, lessen number of inpatient days and hence decrease overall cost.	Tranexamic Acid	104-107	hedgehog interacting protein	Homo sapiens	26-29
34824518-11	2021	Conclusion: Soft splint with the tranexamic acid paste can serve as an effective method of treatment for patients with spontaneous oral bleeding due to medical conditions like GT.	Tranexamic Acid	33-48	POC1 centriolar protein A	Homo sapiens	12-16
34262824-2	2021	The aim of this study was to clarify the following clinical questions: (1) Does the use of tranexamic acid (TXA) reduce the TBL during PSF for AIS? (2) What volume of ABD should be stored to avoid allogeneic blood transfusions?	Tranexamic Acid	91-106	IS1	Homo sapiens	143-147
34262824-2	2021	The aim of this study was to clarify the following clinical questions: (1) Does the use of tranexamic acid (TXA) reduce the TBL during PSF for AIS? (2) What volume of ABD should be stored to avoid allogeneic blood transfusions?	Tranexamic Acid	108-111	IS1	Homo sapiens	143-147
34129752-0	2021	Low blood transfusion rate after implementation of tranexamic acid for fast- track hip- and knee arthroplasty.	Tranexamic Acid	51-66	hedgehog interacting protein	Homo sapiens	83-86
34129752-2	2021	The purpose of this study was to retrospectively evaluate the efficacy of a tranexamic acid (TXA) perioperative protocol for primary hip- and knee arthroplasty, in terms of allogenic blood transfusion rates.	Tranexamic Acid	76-91	hedgehog interacting protein	Homo sapiens	133-136
34129752-2	2021	The purpose of this study was to retrospectively evaluate the efficacy of a tranexamic acid (TXA) perioperative protocol for primary hip- and knee arthroplasty, in terms of allogenic blood transfusion rates.	Tranexamic Acid	93-96	hedgehog interacting protein	Homo sapiens	133-136
35072547-1	2022	PURPOSE: Analyze the impact of Tranexamic acid (TA) use after percutaneous nephrolithotomy (PNL) on blood loss and transfusion rate (TR), and secondary outcomes, complications rate and stone free rates (SFR), Operative time (OT) and length of hospital stay (LOS).	Tranexamic Acid	31-46	coagulation factor II thrombin receptor	Homo sapiens	133-135
35072547-8	2022	Six studies presented a lower blood TR for the TA group (P<0.00001).	Tranexamic Acid	47-49	coagulation factor II thrombin receptor	Homo sapiens	36-38
35636449-8	2022	The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA.	Tranexamic Acid	264-267	interleukin 6	Homo sapiens	170-183
35584211-7	2022	These data suggest that reduced platelet forces lead to an increased bleeding tendency in patients with MYH9-related disease, and treatment with tranexamic acid can improve the hemostatic function.	Tranexamic Acid	145-160	myosin heavy chain 9	Homo sapiens	104-108
35636449-8	2022	The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA.	Tranexamic Acid	33-36	C-reactive protein	Homo sapiens	147-165
35636449-8	2022	The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA.	Tranexamic Acid	33-36	interleukin 6	Homo sapiens	170-183
35636449-8	2022	The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA.	Tranexamic Acid	206-209	C-reactive protein	Homo sapiens	147-165
35636449-8	2022	The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA.	Tranexamic Acid	206-209	interleukin 6	Homo sapiens	170-183
35636449-8	2022	The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA.	Tranexamic Acid	264-267	C-reactive protein	Homo sapiens	147-165
35535540-0	2022	(Hemostatic efficacy of tranexamic acid and epsilon-aminocaproic acid in hip and knee arthroplasty:a Meta-analysis).	Tranexamic Acid	24-39	hedgehog interacting protein	Homo sapiens	73-76
35535540-1	2022	OBJECTIVE: To systematically evaluate the hemostatic efficacy of tranexamic acid and epsilon-aminocaproic acid in total hip arthroplasty (THA) and total knee arthroplasty (TKA).	Tranexamic Acid	65-80	hedgehog interacting protein	Homo sapiens	120-123
35535540-2	2022	METHODS: Randomized controlled trials (RCT) and retrospective case-control studies about tranexamic acid and epsilon-aminocaproic acid for the comparison of THA or TKA were searched electronically in PubMed, EMbase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, VIP from the time of building databases to July 2020.	Tranexamic Acid	89-104	vasoactive intestinal peptide	Homo sapiens	291-294
35545803-4	2022	We previously reported that a self-propelling thrombin-containing powder (SPTP) can be delivered percutaneously into the abdomen as a minimally invasive intervention and can self-disperse through pooled blood to deliver the hemostatic agents thrombin and tranexamic acid (TXA) locally to noncompressible intracavitary wounds.	Tranexamic Acid	255-270	coagulation factor II, thrombin	Sus scrofa	46-54
35545803-4	2022	We previously reported that a self-propelling thrombin-containing powder (SPTP) can be delivered percutaneously into the abdomen as a minimally invasive intervention and can self-disperse through pooled blood to deliver the hemostatic agents thrombin and tranexamic acid (TXA) locally to noncompressible intracavitary wounds.	Tranexamic Acid	272-275	coagulation factor II, thrombin	Sus scrofa	46-54
35545803-4	2022	We previously reported that a self-propelling thrombin-containing powder (SPTP) can be delivered percutaneously into the abdomen as a minimally invasive intervention and can self-disperse through pooled blood to deliver the hemostatic agents thrombin and tranexamic acid (TXA) locally to noncompressible intracavitary wounds.	Tranexamic Acid	272-275	coagulation factor II, thrombin	Sus scrofa	242-250
35220154-2	2022	Tranexamic acid (TXA) reduces the proteolytic action of plasmin on fibrin clots, resulting in an inhibition of fibrinolysis and stabilisation of established blood clots.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	56-63
35105472-1	2022	Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein.	Tranexamic Acid	0-15	kallikrein related peptidase 4	Homo sapiens	187-197
35105472-1	2022	Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein.	Tranexamic Acid	17-20	kininogen 1	Homo sapiens	65-75
35105472-1	2022	Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein.	Tranexamic Acid	17-20	kallikrein related peptidase 4	Homo sapiens	173-183
35105472-1	2022	Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein.	Tranexamic Acid	17-20	kallikrein related peptidase 4	Homo sapiens	187-197
35595664-0	2022	Tranexamic acid use for ACE inhibitor induced angioedema.	Tranexamic Acid	0-15	angiotensin I converting enzyme	Homo sapiens	24-27
35105472-0	2022	Tranexamic acid use in the setting of ACE inhibitor induced angioedema.	Tranexamic Acid	0-15	angiotensin I converting enzyme	Homo sapiens	38-41
35105472-1	2022	Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein.	Tranexamic Acid	0-15	kininogen 1	Homo sapiens	65-75
35105472-1	2022	Tranexamic acid (TXA) is an antifibrinolytic agent which reduces bradykinin production through its blockade of the conversion of plasminogen to plasmin and subsequently pre-kallikrein to kallikrein.	Tranexamic Acid	0-15	kallikrein related peptidase 4	Homo sapiens	173-183
35220154-2	2022	Tranexamic acid (TXA) reduces the proteolytic action of plasmin on fibrin clots, resulting in an inhibition of fibrinolysis and stabilisation of established blood clots.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	56-63
35426283-1	2022	Objective: A prospective randomized controlled trial was conducted to study the effectiveness and safety of intravenous different doses tranexamic acid (TXA) in single-level unilateral minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF).	Tranexamic Acid	136-151	anti-Mullerian hormone	Homo sapiens	244-247
35557600-8	2022	By preventing activated plasmin from de-stabilizing the fibrin matrix, TXA promotes clot formation.	Tranexamic Acid	71-74	plasminogen	Homo sapiens	24-31
35426283-1	2022	Objective: A prospective randomized controlled trial was conducted to study the effectiveness and safety of intravenous different doses tranexamic acid (TXA) in single-level unilateral minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF).	Tranexamic Acid	153-156	anti-Mullerian hormone	Homo sapiens	244-247
35426283-12	2022	Conclusion: Intravenous administration of TXA in single-level unilateral MIS-TLIF is effective and safe in reducing postoperative TBL and HBL within 1 day in a dose-dependent manner.	Tranexamic Acid	42-45	anti-Mullerian hormone	Homo sapiens	73-76
35388589-2	2022	Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss, and is also used to treat rosacea due to its anti-inflammatory effects.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	32-39
35410340-6	2022	RESULTS: TXA administration increased the proportion of circulating CD141+ conventional dendritic cells (cDC) on post-operative day (POD) 3.	Tranexamic Acid	9-12	thrombomodulin	Homo sapiens	68-73
35388589-2	2022	Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss, and is also used to treat rosacea due to its anti-inflammatory effects.	Tranexamic Acid	17-20	plasminogen	Homo sapiens	32-39
35388589-11	2022	The anti-inflammatory effect of TXA resulted in less PIE and PIH.	Tranexamic Acid	32-35	pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included)	Homo sapiens	61-64
35323992-1	2022	Tranexamic acid is a plasmin inhibitor that is used off-label for the treatment of melasma.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	21-28
35265185-1	2022	Background: Tranexamic acid (TXA) has been effective in reducing perioperative blood loss in hip, knee, and shoulder arthroplasty.	Tranexamic Acid	12-27	hedgehog interacting protein	Homo sapiens	93-96
35265185-1	2022	Background: Tranexamic acid (TXA) has been effective in reducing perioperative blood loss in hip, knee, and shoulder arthroplasty.	Tranexamic Acid	29-32	hedgehog interacting protein	Homo sapiens	93-96
2569479-9	1989	Blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with tranexamic acid (IC50 of 5 mM) inhibited neutrophil adherence.	Tranexamic Acid	89-104	plasminogen	Homo sapiens	33-40
34996502-0	2022	Correction to: Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty.	Tranexamic Acid	15-30	hedgehog interacting protein	Homo sapiens	116-119
35389028-23	2022	Oral tranexamic acid complements the topical treatment of melasma by inhibiting the stem cell factor.	Tranexamic Acid	5-20	KIT ligand	Homo sapiens	84-100
35371322-0	2022	Tranexamic acid reduces endometrial cancer effects through the production of angiostatin.	Tranexamic Acid	0-15	plasminogen	Mus musculus	77-88
35371322-6	2022	Furthermore, TA treatment suppressed the levels of carbohydrate antigen 125, interleukin-6, and tumor necrosis factor-alpha in the plasma.	Tranexamic Acid	13-15	interleukin 6	Mus musculus	77-90
35371322-6	2022	Furthermore, TA treatment suppressed the levels of carbohydrate antigen 125, interleukin-6, and tumor necrosis factor-alpha in the plasma.	Tranexamic Acid	13-15	tumor necrosis factor	Mus musculus	96-123
35371322-9	2022	Furthermore, the macrophage counts and the levels of matrix metalloproteinase (MMP)-12 and angiostatin in tumor cells in the uterus increased compared to the corresponding values in the control group and further increased upon TA treatment.	Tranexamic Acid	227-229	matrix metallopeptidase 12	Mus musculus	53-86
35371322-9	2022	Furthermore, the macrophage counts and the levels of matrix metalloproteinase (MMP)-12 and angiostatin in tumor cells in the uterus increased compared to the corresponding values in the control group and further increased upon TA treatment.	Tranexamic Acid	227-229	plasminogen	Mus musculus	91-102
35371322-10	2022	The results of our study indicate that TA ameliorated the endometrial cancer induced by MNU and estradiol by regulating the macrophage/MMP-12/plasminogen/angiostatin signal transmission pathway.	Tranexamic Acid	39-41	matrix metallopeptidase 12	Mus musculus	135-141
35371322-10	2022	The results of our study indicate that TA ameliorated the endometrial cancer induced by MNU and estradiol by regulating the macrophage/MMP-12/plasminogen/angiostatin signal transmission pathway.	Tranexamic Acid	39-41	plasminogen	Mus musculus	154-165
35068314-3	2022	This impact study is aimed to determine the effect of routine prophylactic tranexamic acid during CS on maternal hemorrhage and the rate of the associated side effects.	Tranexamic Acid	75-90	citrate synthase	Homo sapiens	98-100
35068314-9	2022	CONCLUSIONS: The finding of our study suggest that prophylactic administration of TxA prior to CS improves maternal and neonatal outcomes.	Tranexamic Acid	82-85	citrate synthase	Homo sapiens	95-97
35186537-0	2022	Is Tranexamic Acid Safe and Efficacious in Hip Surgeries?	Tranexamic Acid	3-18	hedgehog interacting protein	Homo sapiens	43-46
35186537-5	2022	This study aims to evaluate the efficacy and safety of tranexamic acid in patients undergoing hip surgeries.	Tranexamic Acid	55-70	hedgehog interacting protein	Homo sapiens	94-97
35095503-1	2021	Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin.	Tranexamic Acid	0-15	plasminogen	Homo sapiens	229-236
35095503-1	2021	Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin.	Tranexamic Acid	17-19	plasminogen	Homo sapiens	229-236
35095503-2	2021	Previous studies suggested that TA may exhibit anticancer activity by blockade of extracellular Plasmin formation.	Tranexamic Acid	32-34	plasminogen	Homo sapiens	96-103
35095503-4	2021	Results presented herein demonstrate that TA blocks Plasmin-mediated excision of the extracellular domain of the oncoprotein CDCP1.	Tranexamic Acid	42-44	plasminogen	Homo sapiens	52-59
35095503-4	2021	Results presented herein demonstrate that TA blocks Plasmin-mediated excision of the extracellular domain of the oncoprotein CDCP1.	Tranexamic Acid	42-44	CUB domain containing protein 1	Homo sapiens	125-130
35095503-6	2021	Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production.	Tranexamic Acid	24-26	plasminogen	Homo sapiens	242-249
35095503-6	2021	Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production.	Tranexamic Acid	70-72	plasminogen	Homo sapiens	242-249
35095503-6	2021	Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production.	Tranexamic Acid	158-160	plasminogen	Homo sapiens	242-249
35095503-7	2021	Indeed, TA-mediated suppression of tumor cell viability is associated with multiple biochemical actions, including inhibition of protein synthesis, reduced activating phosphorylation of STAT3 and S6K1, decreased expression of the MYC oncoprotein, and suppression of Lys acetylation.	Tranexamic Acid	8-10	signal transducer and activator of transcription 3	Homo sapiens	186-191
35095503-7	2021	Indeed, TA-mediated suppression of tumor cell viability is associated with multiple biochemical actions, including inhibition of protein synthesis, reduced activating phosphorylation of STAT3 and S6K1, decreased expression of the MYC oncoprotein, and suppression of Lys acetylation.	Tranexamic Acid	8-10	ribosomal protein S6 kinase B1	Homo sapiens	196-200
35095503-7	2021	Indeed, TA-mediated suppression of tumor cell viability is associated with multiple biochemical actions, including inhibition of protein synthesis, reduced activating phosphorylation of STAT3 and S6K1, decreased expression of the MYC oncoprotein, and suppression of Lys acetylation.	Tranexamic Acid	8-10	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	230-233
34654053-10	2022	Low to very low certainty evidence showed that prescribing tranexamic acid and increasing VWF levels to 0.50 IU/mL resulted in less bleeding complications after minor procedures compared to increasing VWF levels to 0.50 IU/mL alone.	Tranexamic Acid	59-74	von Willebrand factor	Homo sapiens	201-204
2551068-0	1989	Inhibition by tranexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: the presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin.	Tranexamic Acid	14-29	plasminogen	Homo sapiens	71-78
2551068-0	1989	Inhibition by tranexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: the presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin.	Tranexamic Acid	14-29	plasminogen	Homo sapiens	118-125
2551068-1	1989	The addition of tranexamic acid inhibited the conversion of single chain tissue plasminogen activator (sct-PA) to its two chain form (tct-PA) by plasmin.	Tranexamic Acid	16-31	plasminogen	Homo sapiens	80-87
2551068-4	1989	The addition of tranexamic acid to the mixture of sct-PA and K4 inhibited the rate of the conversion of sct-PA by plasmin.	Tranexamic Acid	16-31	plasminogen	Homo sapiens	114-121
3115654-4	1987	The inhibitor was shown to be a globulin that was labile at 56 degrees C and bound to lysine; low concentrations of tranexamic acid and of lysine abolished the effects of the inhibitor which suggests that it possesses lysine-binding sites: these may block the CR1-binding site on IC opsonized with complement.	Tranexamic Acid	116-131	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	260-263
2523891-2	1989	We found that after incubation of monolayer cultures with purified native human plasminogen in serum-containing medium, bound plasmin activity could be eluted from the cells with tranexamic acid, an analogue of lysine.	Tranexamic Acid	179-194	plasminogen	Homo sapiens	80-87
2538425-1	1989	After incubation of confluent monolayer cultures of human HT-1080 fibrosarcoma cells with purified native human plasminogen in plasminogen-depleted serum-containing medium, bound plasmin activity could be specifically eluted from the cells with tranexamic acid, an analogue of lysine.	Tranexamic Acid	245-260	plasminogen	Homo sapiens	112-119
3394116-1	1988	Glu-plasminogen (Glu-plg) was degraded by elastase in the presence or absence of tranexamic acid.	Tranexamic Acid	81-96	plasminogen	Homo sapiens	21-24
3394116-2	1988	Glu-plg was degraded faster in the presence of tranexamic acid.	Tranexamic Acid	47-62	plasminogen	Homo sapiens	4-7
2441605-5	1987	Other ovaries were pretreated with trans-4-(aminomethyl)-cyclohexane-carboxylic acid, an inhibitor of the conversion of plasminogen to plasmin, and then perfused with human chorionic gonadotropin (50 IU).	Tranexamic Acid	35-84	plasminogen	Homo sapiens	120-127
3334852-7	1988	These data suggest that the amino residue of Lys-10 and the carboxylic acid of Lys-26 in peptide T-11 play crucial roles in the ionic binding of alpha 2-plasmin inhibitor to the tranexamic acid-binding site (lysine-binding site) of plasminogen.	Tranexamic Acid	178-193	serpin family F member 2	Homo sapiens	145-170
2933845-5	1985	In the presence of 1 mM tranexamic acid, the conversion of both Glu-plg I and II to their Lys-forms by plasmin was accelerated and completed in 30 min incubation.	Tranexamic Acid	24-39	plasminogen	Homo sapiens	103-110
2953634-4	1987	Treatment with AMCA significantly reduced both plasminogen activator (p less than 0.01) and plasmin (p less than 0.05) in the menstrual blood of patients with menorrhagia (Group 3).	Tranexamic Acid	15-19	plasminogen	Homo sapiens	47-54
2943320-7	1986	A rate constant, kcat/Km = 4.4 X 10(3) M-1 X s-1 is obtained for the reaction between plasmin and Glu-1-plasminogen in the presence of 1 mM trans-4-(aminomethyl)cyclohexane-1-carboxylic acid.	Tranexamic Acid	140-190	plasminogen	Homo sapiens	86-93
2933845-8	1985	Another observation was that tranexamic acid protected the degradation of plasminogen by plasmin, indicating the involvement of the lysine binding sites (LBS) of plasmin in the proteolytic attack against plg.	Tranexamic Acid	29-44	plasminogen	Homo sapiens	74-81
2933845-8	1985	Another observation was that tranexamic acid protected the degradation of plasminogen by plasmin, indicating the involvement of the lysine binding sites (LBS) of plasmin in the proteolytic attack against plg.	Tranexamic Acid	29-44	plasminogen	Homo sapiens	89-96
2934862-2	1985	Increases in plasma activity by 125I-fibrin assay were similar (mean increase, 3- to 4-fold) to those observed by euglobulin lysis, and were inhibited (90-93% inhibition) by tranexamic acid at a concentration (10 mmol/l) which inhibits plasmin-mediated fibrinolysis.	Tranexamic Acid	174-189	plasminogen	Homo sapiens	236-243
2934862-7	1985	Thus, the fibrinolytic response to exercise in the majority of normal individuals includes not only the well-known plasmin-mediated increase in plasma, which is inhibitable by tranexamic acid, but also a similar increment in cell-mediated activity, which is due to qualitative functional rather than quantitative changes in one or more as yet unidentified cell types, acting alone or in conjunction with plasma factors which are not inhibited by tranexamic acid.	Tranexamic Acid	176-191	plasminogen	Homo sapiens	115-122
2934862-7	1985	Thus, the fibrinolytic response to exercise in the majority of normal individuals includes not only the well-known plasmin-mediated increase in plasma, which is inhibitable by tranexamic acid, but also a similar increment in cell-mediated activity, which is due to qualitative functional rather than quantitative changes in one or more as yet unidentified cell types, acting alone or in conjunction with plasma factors which are not inhibited by tranexamic acid.	Tranexamic Acid	446-461	plasminogen	Homo sapiens	115-122